WO1999036564A9 - Multiplexed analysis of clinical specimens apparatus and methods - Google Patents
Multiplexed analysis of clinical specimens apparatus and methodsInfo
- Publication number
- WO1999036564A9 WO1999036564A9 PCT/US1999/000918 US9900918W WO9936564A9 WO 1999036564 A9 WO1999036564 A9 WO 1999036564A9 US 9900918 W US9900918 W US 9900918W WO 9936564 A9 WO9936564 A9 WO 9936564A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bead
- beads
- subset
- interest
- sample
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 194
- 238000004458 analytical method Methods 0.000 title description 79
- 239000011324 bead Substances 0.000 claims abstract description 610
- 238000003556 assay Methods 0.000 claims abstract description 345
- 238000000684 flow cytometry Methods 0.000 claims abstract description 115
- 108020004414 DNA Proteins 0.000 claims abstract description 79
- 238000005259 measurement Methods 0.000 claims abstract description 67
- 102000004190 Enzymes Human genes 0.000 claims abstract description 61
- 108090000790 Enzymes Proteins 0.000 claims abstract description 61
- 238000001514 detection method Methods 0.000 claims abstract description 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 21
- 239000000523 sample Substances 0.000 claims description 169
- 239000012491 analyte Substances 0.000 claims description 156
- 108091034117 Oligonucleotide Proteins 0.000 claims description 94
- 239000012530 fluid Substances 0.000 claims description 94
- 108091007433 antigens Proteins 0.000 claims description 92
- 102000036639 antigens Human genes 0.000 claims description 92
- 239000000427 antigen Substances 0.000 claims description 91
- 230000006870 function Effects 0.000 claims description 88
- 210000002966 serum Anatomy 0.000 claims description 88
- 150000007523 nucleic acids Chemical class 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 81
- 108020004707 nucleic acids Proteins 0.000 claims description 81
- 102000039446 nucleic acids Human genes 0.000 claims description 81
- 230000035772 mutation Effects 0.000 claims description 78
- 239000000376 reactant Substances 0.000 claims description 69
- 238000012360 testing method Methods 0.000 claims description 67
- 239000013566 allergen Substances 0.000 claims description 59
- 238000006243 chemical reaction Methods 0.000 claims description 53
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 48
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 48
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 238000009396 hybridization Methods 0.000 claims description 42
- 239000000758 substrate Substances 0.000 claims description 36
- 108060003951 Immunoglobulin Proteins 0.000 claims description 35
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 35
- 102000018358 immunoglobulin Human genes 0.000 claims description 35
- 239000003112 inhibitor Substances 0.000 claims description 35
- 230000000295 complement effect Effects 0.000 claims description 31
- 238000009739 binding Methods 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 18
- 238000010168 coupling process Methods 0.000 claims description 17
- 239000007850 fluorescent dye Substances 0.000 claims description 16
- 230000000875 corresponding effect Effects 0.000 claims description 15
- 230000002860 competitive effect Effects 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 12
- 239000002751 oligonucleotide probe Substances 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 229940072221 immunoglobulins Drugs 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 11
- 239000012070 reactive reagent Substances 0.000 claims description 11
- -1 convertases Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000035935 pregnancy Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 230000002596 correlated effect Effects 0.000 claims description 7
- 238000003066 decision tree Methods 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000003298 DNA probe Substances 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 238000007822 cytometric assay Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 108020003215 DNA Probes Proteins 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000004075 alteration Effects 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 3
- 108010064733 Angiotensins Proteins 0.000 claims description 3
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 3
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 3
- 102000052609 BRCA2 Human genes 0.000 claims description 3
- 108700020462 BRCA2 Proteins 0.000 claims description 3
- 101150008921 Brca2 gene Proteins 0.000 claims description 3
- 241000498849 Chlamydiales Species 0.000 claims description 3
- 102100031867 DNA excision repair protein ERCC-6 Human genes 0.000 claims description 3
- 101000851684 Homo sapiens Chimeric ERCC6-PGBD3 protein Proteins 0.000 claims description 3
- 101000920783 Homo sapiens DNA excision repair protein ERCC-6 Proteins 0.000 claims description 3
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 3
- 108091006671 Ion Transporter Proteins 0.000 claims description 3
- 102000037862 Ion Transporter Human genes 0.000 claims description 3
- 108010001831 LDL receptors Proteins 0.000 claims description 3
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 3
- 241000606651 Rickettsiales Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 241000223997 Toxoplasma gondii Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 108700041737 bcl-2 Genes Proteins 0.000 claims description 3
- 230000006846 excision repair Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 230000033607 mismatch repair Effects 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 238000012289 standard assay Methods 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 230000017105 transposition Effects 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- 108010006591 Apoenzymes Proteins 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 2
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 claims description 2
- 101000582631 Homo sapiens Menin Proteins 0.000 claims description 2
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000003756 cervix mucus Anatomy 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 101150016096 17 gene Proteins 0.000 claims 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims 2
- 102100032187 Androgen receptor Human genes 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- 102100022474 DNA repair protein complementing XP-A cells Human genes 0.000 claims 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 2
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims 2
- 101000618531 Homo sapiens DNA repair protein complementing XP-A cells Proteins 0.000 claims 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 claims 2
- 102000000853 LDL receptors Human genes 0.000 claims 2
- 108090000364 Ligases Proteins 0.000 claims 2
- 102000003960 Ligases Human genes 0.000 claims 2
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 claims 2
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 claims 2
- 101150090410 NEFL gene Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 230000009137 competitive binding Effects 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 240000005611 Agrostis gigantea Species 0.000 claims 1
- 102000003677 Aldehyde-Lyases Human genes 0.000 claims 1
- 108090000072 Aldehyde-Lyases Proteins 0.000 claims 1
- 240000008791 Antiaris toxicaria Species 0.000 claims 1
- 229930194845 Bahia Natural products 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 102000004031 Carboxy-Lyases Human genes 0.000 claims 1
- 108090000489 Carboxy-Lyases Proteins 0.000 claims 1
- 108020005199 Dehydrogenases Proteins 0.000 claims 1
- 241001519376 Distichlis spicata Species 0.000 claims 1
- 108090000371 Esterases Proteins 0.000 claims 1
- 102000004867 Hydro-Lyases Human genes 0.000 claims 1
- 108090001042 Hydro-Lyases Proteins 0.000 claims 1
- 241000245643 Koeleria Species 0.000 claims 1
- 244000147568 Laurus nobilis Species 0.000 claims 1
- 235000017858 Laurus nobilis Nutrition 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 102100030550 Menin Human genes 0.000 claims 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
- 108010071195 Nucleotidases Proteins 0.000 claims 1
- 102000007533 Nucleotidases Human genes 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 102000009097 Phosphorylases Human genes 0.000 claims 1
- 108010073135 Phosphorylases Proteins 0.000 claims 1
- 241000287219 Serinus canaria Species 0.000 claims 1
- 101710120037 Toxin CcdB Proteins 0.000 claims 1
- 102000003929 Transaminases Human genes 0.000 claims 1
- 108090000340 Transaminases Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 235000011073 invertase Nutrition 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 238000010223 real-time analysis Methods 0.000 abstract description 20
- 230000002068 genetic effect Effects 0.000 abstract description 14
- 238000012252 genetic analysis Methods 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 2
- 239000004005 microsphere Substances 0.000 description 155
- 238000003752 polymerase chain reaction Methods 0.000 description 69
- 239000000047 product Substances 0.000 description 56
- 230000005764 inhibitory process Effects 0.000 description 38
- 108700028369 Alleles Proteins 0.000 description 37
- 241000282472 Canis lupus familiaris Species 0.000 description 35
- 241000283707 Capra Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 33
- 244000025254 Cannabis sativa Species 0.000 description 32
- 101100449439 Drosophila melanogaster grass gene Proteins 0.000 description 32
- 230000009257 reactivity Effects 0.000 description 30
- 239000012071 phase Substances 0.000 description 28
- 238000010790 dilution Methods 0.000 description 24
- 239000012895 dilution Substances 0.000 description 24
- 238000012216 screening Methods 0.000 description 23
- 239000013642 negative control Substances 0.000 description 22
- 201000005404 rubella Diseases 0.000 description 21
- 229960002685 biotin Drugs 0.000 description 20
- 239000011616 biotin Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 238000005119 centrifugation Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 230000006957 competitive inhibition Effects 0.000 description 16
- 238000007781 pre-processing Methods 0.000 description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 230000009260 cross reactivity Effects 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 229920001213 Polysorbate 20 Polymers 0.000 description 11
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 11
- 238000004448 titration Methods 0.000 description 11
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000003068 molecular probe Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000010911 Enzyme Precursors Human genes 0.000 description 7
- 108010062466 Enzyme Precursors Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 150000001718 carbodiimides Chemical class 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 108090001008 Avidin Proteins 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 102000054766 genetic haplotypes Human genes 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 239000012048 reactive intermediate Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000012064 sodium phosphate buffer Substances 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 101100422147 Danio rerio spns1 gene Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 241000609499 Palicourea Species 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000579895 Chlorostilbon Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000010420 art technique Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229910052876 emerald Inorganic materials 0.000 description 4
- 239000010976 emerald Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000013198 immunometric assay Methods 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 108010087904 neutravidin Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000009830 antibody antigen interaction Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108700001666 APC Genes Proteins 0.000 description 2
- 241000260460 Buteogallus Species 0.000 description 2
- JFLRKDZMHNBDQS-UCQUSYKYSA-N CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C Chemical compound CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C JFLRKDZMHNBDQS-UCQUSYKYSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 230000010558 Gene Alterations Effects 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 108700005089 MHC Class I Genes Proteins 0.000 description 2
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 2
- 101100000208 Mus musculus Orm2 gene Proteins 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000004848 nephelometry Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- MRBDCXIPGTYKQU-VJNPKTSZSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical group NCC(O)=O.NCCCC[C@H](N)C(O)=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 MRBDCXIPGTYKQU-VJNPKTSZSA-N 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 206010010539 Congenital megacolon Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 208000001825 Hereditary elliptocytosis Diseases 0.000 description 1
- 101150016456 Hexa gene Proteins 0.000 description 1
- 208000004592 Hirschsprung disease Diseases 0.000 description 1
- PZUZIHRPOVVHOT-KBPBESRZSA-N His-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CN=CN1 PZUZIHRPOVVHOT-KBPBESRZSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000007599 Hyperkalemic periodic paralysis Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 101150083321 Nf1 gene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001668545 Pascopyrum Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000028167 Southeast Asian ovalocytosis Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000035954 Thomsen and Becker disease Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 101150029162 Xpac gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000033654 autosomal recessive myotonia congenita Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- LVKZSFMYNWRPJX-UHFFFAOYSA-N benzenearsonic acid Natural products O[As](O)(=O)C1=CC=CC=C1 LVKZSFMYNWRPJX-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000009601 hereditary spherocytosis Diseases 0.000 description 1
- 101150048127 hlgA gene Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000054064 human MBP Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 238000012184 no-wash assay format Methods 0.000 description 1
- 108010028584 nucleotidase Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229920006012 semi-aromatic polyamide Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000000059 tachyzoite Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- Microfiche appendix A contains a listing of selected Visual Basic and C programming source code in accordance with the inventive multiplexed assay method.
- Microfiche appendix A comprising 1 sheet having a total of 58 frames, contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent disclosure, as it appears in the Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.
- the invention relates generally to laboratory diagnostic and genetic analysis and, more particularly, to a flow cytometric method for the simultaneous and multiplexed diagnostic and genetic analysis of clinical specimens.
- multiplexing a capability to perform simultaneous, multiple determinations in a single assay process is known as “multiplexing” and a process to implement such a capability is a “multiplexed assay.”
- Flow cytometry is an optical technique that analyzes particular particles in a fluid mixture based on the particles' optical characteristics using an instrument known as a flow cytometer. Background information on flow cytometry may be found in Shapiro, "Practical Flow Cytometry,” Third Ed. (Alan R.
- Flow cytometers hydrodynamically focus a fluid suspension of particles into a thin stream so that the particles flow down the stream in substantially single file and pass through an examination zone.
- a focused light beam such as a laser beam illuminates the particles as they flow through the examination zone.
- Optical detectors within the flow cytometer measure certain characteristics of the light as it interacts with the particles.
- Commonly used flow cytometers such as the Becton-Dickinson Immunocytometry Systems "F ACS CAN" (San Jose, CA) can measure forward light scatter (generally correlated with the refractive index and size of the particle being illuminated), side light scatter (generally correlated with the particle's size), and particle fluorescence at one or more wavelengths.
- microspheres or beads for use in flow cytometry are generally known in the art and may be obtained from manufacturers such as Spherotech (Libertyville, IL), and Molecular Probes (Eugene, OR). Although a multiplexed analysis capability theoretically would provide enormous benefits in the art of flow cytometry, very little multiplexing capability has been previously achieved. Prior multiplexed assays have obtained only a limited number of determinations.
- McHugh Flow Microsphere Immunoassay for the Quantitative and Simultaneous Detection of Multiple Soluble Analytes
- Methods in Cell Biology, 42, Part B, (Academic Press, 1994) For example, McHugh et al., “Microsphere-Based Fluorescence Immunoassays Using Flow Cytometry Instrumentation,” in Clinical Flow Cytometry Ed. K.D. Bauer, et al., Williams and Williams, Baltimore, MD, 1993, 535-544, describe an assay where microspheres of different sizes are used as supports and the identification of microspheres associated with different analytes was based on distinguishing a microsphere's size.
- PCR polymerase chain reaction
- the power and sensitivity of the PCR has prompted its application to a wide variety of analytical problems in which detection of DNA or RNA sequences is required.
- PCR is capable of amplifying short fragments of DNA, providing short (20 bases or more) nucleotides are supplied as primers.
- the primers anneal to either end of a span of denatured DNA target and, upon renaturation, enzymes synthesize the intervening complementary sequences by extending the primer along the target strand.
- the temperature is raised to break apart the target and newly synthesized complementary sequence.
- primers Upon cooling, renaturation and annealing, primers bind to the target and the newly made opposite strand and now the primer is extended again creating the complement. The result is that in each cycle of heating and renaturation followed by primer extension, the amount of target sequence is doubled.
- That method involves amplifying a DNA sequence suspected of containing the disease associated mutation, combining the amplified product with an RNA probe to produce an RNA-DNA hybrid and detecting the mutation by digesting unhybridized portions of the RNA strand by treating the hybridized product with an RNAse to detect mutations, and then measuring the size of the products of the RNAse reaction to determine whether cleavage of the RNA molecule has occurred.
- the avidin beads bearing the annealed complementary material were then processed by a flow cytometer.
- the procedure was limited, inter alia, in that avidin beads having only a single specificity were employed. Further, real-time analysis of the assay's data was not possible.
- the present invention enables the simultaneous determination of multiple distinct analytes to a far greater degree than existing techniques. Further, the invention provides an improved data classification and analysis methodology that enables the meaningful t analysis of highly multiplexed assays in real-time.
- the invention is broadly applicable to multiplexed analysis of a number of analytes in a host of bioassays in which there is currently a need in the art.
- the present invention provides improved methods, instrumentation, and products for detecting multiple analytes in a fluid sample by flow cytometric analysis and for analyzing and presenting the data in real-time.
- An advantage of the invention is that it allows one rapidly and simultaneously to detect a wide variety of analytes of interest in a single assay step.
- the invention employs a pool of bead subsets. The individual subsets are prepared so that beads within a subset are relatively homogeneous but differ in at least one distinguishing characteristic from beads in any other subset. Therefore, the subset to which a bead belongs can readily be determined after beads from different subsets are pooled.
- the beads within each subset are uniform with respect to at least three and preferably four known classification parameter values measured with a flow cytometer: e.g., forward light scatter (C,) which generally correlates with size and refractive index; side light scatter (C 2 ) which generally correlates with size; and fluorescent emission in at least one wavelength (C 3 ), and preferably in two wavelengths (C 3 and C 4 ), which generally results from the presence of fluorochrome(s) in or on the beads.
- a bead's subset identity can be verified during flow cytometric analysis of the pool in a single assay step and in real-time.
- the beads within each subset can be coupled to a reactant that will specifically react with a given analyte of interest in a fluid sample to be tested.
- a reactant that will specifically react with a given analyte of interest in a fluid sample to be tested.
- different subsets will be coupled to different reactants so as to detect different analytes.
- subset 1 may be labeled so as to detect analyte A (AnA);
- subset 2 may be labeled so as to detect analyte B (AnB); etc.
- the variously labeled subsets are pooled.
- the pooled beads, or beadset are then mixed with a fluid sample to test for analytes reactive with the various reactants bound to the beads.
- the system is designed so that reactions between the reactants on the bead surfaces and the corresponding analytes in the fluid sample will cause changes in the intensity of at least one additional fluorescent signal (F m ) emitted from a fluorochrome that fluoresces at a wavelength distinct from the wavelengths of classification parameters C 3 or C 4 .
- the F m signal serves as a "measurement signal," that is, it indicates the extent to which the reactant on a given bead has undergone a reaction with its corresponding analyte.
- the F m signal may result from the addition to the assay mixture of fluorescently labeled "secondary" reagent that binds to the bead surface at the site where a reactant-analyte reaction has occurred.
- the classification parameters e.g., C,, C 2 , C 3 , and C 4 , are measured and used to classify each bead into the subset to which it belongs and, therefore, identify the analyte that the bead is designed to detect.
- the F m value of the bead is determined to indicate the concentration of analyte of interest in the fluid sample.
- Measured F m values for all b ⁇ ads assayed and classified as belonging to a given subset may be averaged or otherwise manipulated statistically to give a single meaningful data point, displayed in histogram format to provide information about the distribution of F, hormone values within the subset, or analyzed as a function of time to provide information about the rate of a reaction involving that analyte.
- the beads will have two or more fluorochromes incorporated within or on them so that each of the beads in a given subset will possess at least four different classification parameters, e.g., C h C 2 , C 3 , and C 4 .
- the beads may be made to contain a red fluorochrome (C 3 ), such as nile red. and bear an orange fluorochrome (C ), such as Cy3 or phycoerythrin.
- C 3 red fluorochrome
- C orange fluorochrome
- a third fluorochrome such as fluorescein, may be used as a source of the C fatigue or F m signal.
- additional fluorochromes may be used to generate additional C Cosmetic signals. That is, given suitable fluorochromes and equipment, those of skill in the art may use multiple fluorochromes to measure a variety of C Cincinnati o F m values, thus expanding the multiplexing power of the system even further.
- multiple subsets of beads may be coupled to the same reactant but at varying concentrations so as to produce subsets of beads varying in density of bound reactant rather than in the type of reactant.
- the reactant associated with classification parameter C 4 may be incorporated directly into the reactive reagent that is coupled to the beads, thereby allowing C 4 conveniently to serve as an indicator of density of reactant on the bead surface as well as an indicator of reactant identity.
- each subset differing from the other subsets in one or more of Cj, C 2 , or C 3 .
- Each of those subsets may be further subdivided into a number of aliquots.
- Beads in each aliquot may be coupled with a reactant of choice that has been fluorescently labeled with a fluorochrome associated with C (e.g., Analyte A labeled with Cy3) under conditions such that the concentration or density of reactant bound to the beads of each aliquot will differ from that of each other aliquot in the subset.
- a fluorochrome associated with C e.g., Analyte A labeled with Cy3
- an entire subset may be treated with the C 4 fluorochrome under conditions that produce a heterogeneous distribution of C 4 reactant on beads within the subset.
- the subset may then be sorted with a cell sorter on the basis of the intensity of C 4 to yield further subsets that differ from one another in C 4 intensity.
- C 4 labeled reactant as a classification agent
- the number of subsets that can be prepared and used in practice of the invention is theoretically quite high, but in practice will depend, inter alia, on the level of homogeneity within a subset and the precision of the measurements that are obtained with a flow cytometer.
- the intra-subset heterogeneity for a given parameter e.g., forward angle light scatter C /
- Bead subsets may be subjected to flow cytometric sorting or other procedures at various different points in preparation or maintenance of the bead subsets to increase homogeneity within the subset.
- flow cytometric sorting or other procedures at various different points in preparation or maintenance of the bead subsets to increase homogeneity within the subset.
- more heterogeneity can be allowed within a subset without compromising the reliability of the assay.
- the beads are used to test for a variety of antibodies in a fluid sample.
- a panel of bead subsets having known varying C h C 2 , C 3 , and C 4 values is first prepared or otherwise obtained.
- the beads within each subset are then coupled to a given antigen of interest.
- Each subset receives a different antigen.
- the subsets are then pooled to form an assay beadset and may be stored for later use and/or sold as a commercial test kit.
- the beads are mixed with the fluid to be analyzed for antibodies reactive with the variety of antigens carried on the beads under conditions that will permit antigen-antibody interaction.
- the beads are labeled with a "secondary" reagent that binds to antibodies bound to the antigens on the beads and that also bears the measurement fluorochrome associated with parameter F m (e.g., fluorescein).
- F m e.g., fluorescein
- a fluoresceinated antibody specific for immunoglobulin may be used for this purpose.
- the beads are then run through a flow cytometer, and each bead is classified by its characteristic classification parameters as belonging to subset- 1, subset-2, etc.
- the presence of antibodies specific for antigen A, B, etc. can be detected by measuring green fluorescence, F m , of each bead.
- the classification parameters , C 2 , C 3 , and C 4 allow one to determine the subset to which a bead belongs, which serves as an identifier for the antigen carried on the bead.
- the F m value of the bead indicates the extent to which the antibody reactive with that antigen is present in the sample.
- assays for antibodies were used above as an illustration, those of ordinary skill in the art will recognize that the invention is not so limited in scope, but is widely applicable to detecting any of a number of analytes in a sample of interest.
- the methods described here may be used to detect enzymes or DNA or virtually any analyte detectable by virtue of a given physical or chemical reaction.
- a number of suitable assay procedures for detection and quantification of enzymes and DNA are described in more detail below.
- the present invention also provides a significant advance in the art by providing a rapid and sensitive flow cytometric assay for analysis of genetic sequences that is widely applicable to detection of RNA, differing alleles, and any of a number of genetic abnormalities.
- the methods of the present invention employ a competitive hybridization assay using DNA coupled microspheres and fluorescent DNA probes.
- Probes and microsphere-linkedoligonucleotidescould also include RNA, PNA, and non-natural nucleotide analogs.
- oligonucleotides from a region of a gene of interest are synthesized and coupled to a microsphere (bead) by standard techniques such as by carbodiimide coupling.
- DNA which is to be tested is purified and either assayed unamplified, or subjected to amplification by PCR, RT-PCR, or LCR amplification using standard techniques and PCR initiation probes directed to amplify the particular region of DNA of interest.
- the PCR product is then incubated with the beads under conditions sufficient to allow hybridization between the amplified DNA and the oligonucleotides present on the beads.
- a fluorescent DNA probe that is complementary to the oligonucleotide coupled to the beads is also added under competitive hybridization conditions. Aliguots of the beads so reacted are then run through a flow cytometer and the intensity of fluorescence on each bead is measured to detect the level of fluorescence which indicates the presence or absence of given sequences in the samples.
- the PCR product will effect a significant competitive displacement of fluorescent oligonucleotide probe from the beads and, therefore, cause a measurable decrease in fluorescence of the beads, e.g., as compared to a control reaction that did not receive PCR reaction product.
- a PCR product from an individual having a mutation in the region of interest is incubated with the beads bearing the wild-type probe, a significantly lesser degree of displacement and resulting decrease in intensity of fluorescence on the beads will be observed because the mutated PCR product will be a less effective competitor for binding to the oligonucleotide coupled to the bead than the perfectly complementary fluorescent wild-type probe.
- the beads may be coupled to an oligonucleotide corresponding to a mutation known to be associated with a particular disease and similar principles applied.
- bead subsets are prepared with all known, or possible, variants of the sequence of interest and then mixed to form a bead set.
- test sample e.g. PCR product
- wild-type sequence and other variants can then be assayed simultaneously.
- the relative reactivity of the PCR product with subsets bearing the wild-type or variant sequences identifies the sequence of the PCR product.
- the matrix of information derived from this type of competitive hybridization in which the test sequence and the entire panel of probe sequences react simultaneously allows identification of the PCR product as wild-type, known mutant, or unknown mutant.
- the invention thus provides one with the ability to measure any of a number of genetic variations including point mutations, insertions, deletions, inversions, and alleles in a simple, appropriately sensitive, and efficient format.
- Figure 1 is a block diagram of an illustrative hardware system for performing a multiplex assay method in accordance with the invention.
- Figure 2 is a block diagram of an illustrative software system for performing a multiplex assay method in accordance with the invention.
- Figure 3 is a flow-chart for a preprocessing phase in accordance with the inventive multiplexed assay method.
- Figure 4 shows an assay database in accordance with the invention.
- Figure 5 shows a baseline data acquisition table for an illustrative multiple analyte assay in accordance with the invention.
- Figure 6 shows an assay definition table in accordance with the invention.
- Figure 7 shows a discriminant table for an illustrative multiple analyte assay in accordance with the invention.
- Figure 8 shows a decision tree view of the illustrative discriminant function table of Figure 7.
- Figure 9 is a flow-chart for a real-time analysis phase of a multiple analyte assay in accordance with the invention.
- Figure 10 shows a results table for an illustrative multiple analyte assay in accordance with the invention.
- Figure 1 1 shows a interpretation table for an illustrative multiple analyte assay in accordance with the invention.
- Figure 12 is a flow-chart for an interpretation phase of a multiple analyte assay in accordance with the invention
- Figures 13a through 13e show an assay database in accordance with the invention for a specific experimental example.
- Figure 14 shows a decision tree view for an illustrative (experimental example) discriminant table.
- Figures 15a, 15b, and 15c show individual inhibition assays for IgG, IgA, and IgM antibodies.
- Figures 16a, 16b, and 16c show cross reactivity determinations between IgG, IgA, and 5 IgM assay components.
- Figure 17 shows the determination of human IgG concentrations by flow cytometry.
- Figure 18 shows the determination of human IgA concentrations by flow cytometry.
- Figure 19 shows the determination of human IgM concentrations by flow cytometry.
- Figure 20 shows the simultaneous determination of human IgG, IgA, and IgM concentrations by flow cytometry. 5
- Figure 21 shows the specificity of monoclonal antibody MAB384 binding towards bead immobilized epitope sequences.
- Figure 22 shows the specificity of monoclonal antibody MAB384 binding in the & presence of soluble epitope containing peptide.
- Figure 23 shows the specificity of monoclonal antibody MAB384 binding in the presence of soluble biotin.
- Figure 24 shows the detection of anti-Rubella IgG antibodies by a sandwich assay between rubella coated beads and a fluorescent goat anti-human IgG antibody.
- Figure 25 shows a calibration assay using serial dilutions of anti-Rubella IgG antibodies in a sandwich assay between rubella coated beads and a fluorescent goat anti-human IgG 0 antibody.
- Figures 26a and 26b show the simultaneous assay for six anti-ToRCH IgG, and simultaneous assay for the six anti-ToRCH IgM antibodies.
- Figure 27 shows the determination of IgG anti-grass allergen activities for six dogs.
- Figure 28 shows the determination of IgE anti-grass allergen activities for six dogs.
- Figure 29 shows the multiple analyte IgG and IgE screening of dog ⁇ rum A96324 for sixteen grass allergens
- Figure 30 shows the multiple analyte IgG and IgE screening of dog serum A96325 for sixteen grass allergens
- Figure 31 shows the multiple analyte IgG and IgE screening of dog serum A96319 for sixteen grass allergens
- Figure 32 shows the multiple analyte IgG and IgE screening of dog serum A96317 for sixteen grass allergens
- Figure 33 shows the multiple analyte IgG and IgE screening of dog serum A96326 for sixteen grass allergens
- Figure 34 shows the multiple analyte IgG and IgE screening of dog serum A96323 for sixteen grass allergens
- Figure 35 shows an antibody pair analysis for use with a human chorionic gonadotropin capture assay.
- Figure 36 shows the use of bead linked antibody MAB602 with fluorescently labeled antibody AB633 in a human chorionic gonadotropin capture assay.
- Figure 37a and 37b show cross reactivity analyses between components of an anti-hCG capture system and an anti-AFP capture system.
- Figures 38a and 38b compare the effects of eliminating wash steps in hCG and AFP capture system assays.
- Figures 39a and 39b show the determination of hCG and AFP concentrations in samples and standards using a homogeneous capture assay format.
- Figure 40 shows the inhibition of Anti-IgG binding to bead based IgG by soluble IgG antibodies. Inhibition was determined at five concentrations of soluble IgG, and four IgG loading levels on the beads.
- Figure 41 shows the slope of the inhibition pattern across the four loading levels of IgG on the beads plotted against the soluble IgG concentration.
- Figure 42 shows a five point standard curve derived from inhibition data of the 50 ⁇ g/mL IgG bead set.
- Figures 43a through 43c show DNA detection using a double stranded competitor and a wild-type "B" oligonucleotideprobe.
- Figures 44a and 44b show DNA detection using a single stranded competitor and a wild- type "B" oligonucleotideprobe.
- Figure 45 shows the differentiation by orange and red fluorescence of fourteen bead sets.
- Figure 46 shows a titration of a fluorescent oligonucleotide in the presence or absence of an inhibitor. Beads bearing complementary oligonucleotides were used in a capture assay.
- Figure 47 shows the inhibition of binding between a fluorescent oligonucleotide and its complementary oligonucleotide bound to a bead. Varying concentrations of complementary and point mutant competitors were used in the determination.
- Figure 48 shows the efficacy of inhibitors across fourteen DNA sequence binding sets.
- Figure 49 shows the typing of four simulated alleles of DQA1.
- Figure 50 shows the typing of five known, homozygous DQA1 alleles.
- Figures 51a through 5 If show the results of an exemplary multiplexed assay according to the invention.
- assay components and methods for the measurement of enzymes, DNA fragments, antibodies, and other biomolecules are provided.
- inventive technology improves the speed and sensitivity of flow cytometric analysis while reducing the cost of performing diagnostic and genetic assays.
- a multiplexed assay in accordance with the invention enables the simultaneous automated assay of multiple (at least an order of magnitude greater than available in the prior techniques) biomolecules or DNA sequences in real-time.
- Beadsets may be prepared, for example, so as to detect or screen for any of a number of sample characteristics, pathological conditions, or reactants in fluids. Beadsets may be designed, for example, to detect antigens or antibodies associated with any of a number of infectious agents including (without limitation, bacteria, viruses, fungi, mycoplasma, rickettsia, chlamydia, and protozoa), to assay for autoantibodies associated with autoimmune disease, to assay for agents of sexually transmitted disease, or to assay for analytes associated with pulmonary disorders, gastrointestinal disorders, cardiovascular disorders, and the like.
- the beadset may be designed to detect any of a number of substances of abuse, environmental substances, or substances of veterinary importance.
- An advantage of the invention is that it allows one to assemble a panel of tests that may be run on an individual suspected of having a syndrome to simultaneously detect a causative agent for the syndrome.
- Suitable panels may include, for example, a tumor marker panel including antigens such as prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), and other suitable tumor markers; a regional allergy panel including pollen and allergens tested for by allergists of a particular region and comprising allergens known to occur in that region; a pregnancy panel comprising tests for human chorionic gonadotropin, hepatitis B surface antigen, rubella virus, alpha fetoprotein, 3' estradiol, and other substances of interest in a pregnant individual; a hormone panel comprising tests for T4, TSH, and other hormones of interests; an autoimmune disease panel comprising tests for rheumatoid factors and antinuclear antibodies and other markers associated with autoimmune disease; a blood borne virus panel and a therapeutic drug panel comprising tests for Cyclosporin, Digoxin, and other therapeutic drugs of interest.
- PSA prostate-specific antigen
- CEA carcinoembryonic antigen
- An important feature of the flow cytometric technology and techniques described here is the fabrication and use of particles (e.g., microspheres or beads that make up a beadset). It is through the use of appropriately labeled homogeneous bead subsets, combined to produce a pooled beadset, that the instant multiplexed assay method is practiced.
- Beads suitable for use as a starting material in accordance with the invention are generally known in the art and may be obtained from manufacturers such as Spherotech (Libertyville, IL) and Molecular Probes (Eugene, OR). Once a homogeneous subset of beads is obtained, the beads are labeled with an appropriate reactant such as a biomolecule, DNA sequence, and/or other reactant.
- an appropriate reactant such as a biomolecule, DNA sequence, and/or other reactant.
- Known methods to incorporate such labels include polymerization, dissolving, and attachment.
- a Method for the Multiplexed Assay of Clinical Samples Development of a multiplexed assay for use in accordance with the invention can be divided into three phases: (1) preprocessing, (2) real-time analysis, and (3) interpretation.
- baseline data is collected independently, via flow cytometric techniques, for each of an assay's bead subsets.
- Baseline data is used to generate a set of functions that can classify any individual bead as belonging to one of the assay's subsets or to a rejection class.
- flow cytometric measurements are used to classify, in real-time, each bead within an exposed beadset according to the aforementioned functions. Additionally, measurements relating to each subset's analyte are accumulated.
- the assay's real-time numerical results are associated with textual explanations and these textual explanations are displayed to a user.
- the inventive method allows the detection of a plurality of analytes simultaneously during a single flow cytometric processing step.
- Benefits of the inventive multiplex assay method include increased speed and reduced cost to analyze a clinical sample.
- FIG. 1 shows, in block diagram form, a system for implementing the inventive multiplexed assay method.
- Flow cytometer 100 output consists of a series of electrical signals indicative of one or more specified measured characteristics on each bead processed. These measurement signals are transmitted to computer 105 via data bus 110 and interface board 115.
- the signals are used by the computer to generate an assay database.
- the signals are processed by the computer (using the assay database) in accordance with the inventive method to produce a multiplexed/simultaneous assay of a clinical sample.
- Flow cytometer 100 operates in a conventional manner. That is, beads are processed by illuminating them, essentially one at a time, with a laser beam. Measurements of the scattered laser light are obtained for each illuminated bead by a plurality of optical detectors. In addition, if a bead contains at least one appropriate fluorescing compound it will fluoresce when illuminated. A plurality of optical detectors within the flow cytometer measure fluorescence at a plurality of wavelengths. Typical measured bead characteristics include, but are not limited to, forward light scatter, side light scatter, red fluorescence, green fluorescence, and orange fluorescence.
- green fluorescent markers or labels can cause cross-channel interference between optical detectors designed to detect green and orange wavelengths (e.g., approximately 530 nanometers and approximately 585 nanometers respectively).
- a training set of beads, in combination with standard data manipulation, can correct for this cross-channel interference by providing the physical measurements required for mathematical correction of the fluorescence measurements.
- Computer 105 can be a conventional computer such as a personal computer or engineering workstation.
- the computer is a personal computer having an Intel "486” processor, running Microsoft Corporation's "WINDOWS” operating system, and a number of ISA expansion slots.
- Interface board 115 is designed to plug into one of the computer's 100 ISA (Industry Standard Architecture) expansion slots. While the design of an interface board is, in general, different for each specific type of flow cytometer 100, its primary functions include (1) receiving and parsing measurement data signals generated by the flow cytometer's detectors, (2) receiving control parameter status information from the flow cytometer, and (3) sending control parameter commands to the flow cytometer. The precise manner in which these functions are carried out are dependent upon the type (make and model) of the flow cytometer used. In one embodiment, employing a Becton-Dickinson "FACSCAN" flow cytometer (San Jose, CA), the interface board uses control signals generated by the flow cytometer to distinguish measurement data and flow cytometer parameter and control signals. Measured data include forward light scatter, side light scatter, red fluorescence, green fluorescence, and orange fluorescence. Parameter and control signals include flow cytometer amplifier gain adjustments and status information.
- ISA Industry Standard Architecture
- an interface board 115 for use with the inventive assay method would be a routine task for one skilled in the art of diagnostic medical equipment design having the benefit of this disclosure
- an important aspect for any interface board is its ability to accommodate the transmission data rate generated by whatever flow cytometer is used.
- the "FACSCAN" flow cytometer can transmit a 16-bit (2 byte) word every 4 microseconds resulting in burst data rates of 500,000 bytes per second.
- Microfiche appendix A provides a detailed source code embodiment of the inventive assay method for use with the "FACSCAN" flow cytometer.
- Data bus 115 provides a physical communication link between the flow cytometer 100 and the interface board 110. Its physical and electrical characteristics (e.g., data width and bandwidth) are dependent upon the capabilities of the flow cytometer. It is noted that the data bus need not be a totally digital bus. If the flow cytometer does not include analog-to-digital conversion of measured bead characteristics (e.g., light scatter and fluorescence signals), then the data bus must communicate these analog signals to the interface board. It is then necessary that digital conversion of these signals be provided by either the interface board or another peripheral device before the data is transmitted to the computer 105.
- analog-to-digital conversion of measured bead characteristics e.g., light scatter and fluorescence signals
- GUI graphical user interface
- DLL dynamically linked library
- the "FACSCAN" flow cytometer can process, or measure, approximately 2,000 beads per second, where each bead is associated with eight 16-bit data values.
- the DLL should be able to accept, and process, at a consistent data rate of at least 32,000 bytes per second. The need to accommodate this data rate, while also having sufficient time to perform real-time analysis based on the data, will generally necessitate that some of the DLL code be written in assembly language.
- GUI 200 is implemented in the visual basic programming language and the DLL 205 is implemented in C and assembly language programming, Microfiche appendix A contains source code listings for one embodiment of the GUI and DLL.
- a function of the preprocessing phase is to generate an assay database for use during the real-time analysis of an exposed beadset (clinical sample).
- preprocessing is performed prior to combining separately labeled bead subsets to form assay beadsets.
- Assay definition, discriminant function definition, and interpretation tables are created at the time an assay beadset is created.
- Figure 3 shows, in flow chart form, the steps taken during the preprocessing phase.
- a bead subset is characterized by (1) the analyte it is designed to identify, (2) one or more classification parameters Cj ... C selfish, and (3) one or more measurement parameters F ml - F ⁇ .
- the classification parameters are used to generate a set of functions, referred to as discriminant functions, that can classify a bead as belonging to one of the assay's subsets or a rejection class.
- Measurement parameters are used during the real-time analysis phase to determine if a specified analyte is present in the clinical sample being analyzed.
- each bead subset contains an equal number of beads.
- the precise number of beads within any given bead subset can vary depending upon many factors including, but not limited to, the number of analytes an assay beadset is designed to detect, the uniformity of the labeled beads (with respect to each of the measured parameters C, ... C n , F m! ... F nx ), and the penalty of misclassifying (e.g., making a type 1 or type 2 classification error) a bead during analysis.
- each bead in an unexposed subset is measured by a flow cytometer 100 and the resulting data values accumulated for later use 300. For example, if the flow cytometer measures n classification parameters and x measurement parameters, i.e., generates (n + x) values for each bead, data for each of the subset's (n + x) parameters are updated based on each bead's measurements. This data collection step is repeated independently for each subset in the assay's beadset 305. The collection of such data for each of an assay's subsets constitutes an assay's baseline data.
- a set of discriminant functions are determined 310.
- the discriminant functions are used to classify a bead into one of the assay's bead subsets or a rejection class based solely on the measured classification parameters, C j ... C n .
- This step in principle and practice, is a problem of multidimensional classification or cluster analysis. Many prior art techniques and commercial software programs exist to perform this task.
- Beads are generally manufactured in large quantities referred to as batches. Each bead in a batch is of nearly identical size and has substantially the same dye absorption capacity. In light of this manufacturing process, bead subsets can be created using precise dilutions of chosen dyes and. because of their nearly identical size, all classification parameters will exhibit essentially equal variances. By correcting for scaling of the photo-multipliers within a flow cytometer, a linear classification rule can be generated. Further, since there are equal quantities of beads in each subset, the prior probabilities will be equal. This allows use of Fisher's linear discriminant technique to calculate the discriminant functions which define classification boundaries.
- linear hierarchical discriminant functions may be chosen which are equidistant, in a Euclidean sense, between the centers or centroids of any two of an assay's bead subsets.
- other types of discriminant functions such as quadratic functions and those discriminating on more than two classification parameters at once, are also possible.
- a set of threshold values are chosen which are used during the real-time analysis phase to detect the presence of a target analyte. For example, assume measurement parameter F m! is used to detect analyte-A. During preprocessing, the baseline or unexposed value for F m! is measured and accumulated for that subset's beads. Analyte-A's threshold could then, for example, be set to F m s baseline mean value plus one standard deviation of F ml 's baseline value.
- the precise function or value selected for a threshold depends upon the parameter being measured (e.g., its distribution) and the cost of making a classification error (e.g., a type 1 or a type 2 error). It is routine that such values be based on an empirical review of the baseline data. The important criterion is that the threshold reliably distinguish between the presence and absence of the target analyte in an exposed assay beadset.
- an assay database is generated 315. Assay Database
- an assay database 400 consists of an assay definition table 405, a discriminant function table 410, a results table 415, and an interpretation table 420. See Figure 4.
- the assay definition table 405 defines an assay which, as described above, comprises two or more bead subsets each of which is designed to detect a specified analyte.
- Each row in the assay definition table describes a bead subset and contains the following entries: (1) assay name, (2) subset name, (3) subset token, (4) baseline values for each of the subset's measurement parameters F ml - F mx , and (5) test-type token.
- the subset name entry is a text string identifying the subset by, for example, the type of analyte it is labeled to detect.
- the subset token is a unique subset identifier.
- the measurement parameter baseline entries are used during the interpretation phase to associate a numerical result (collected during the real-time analysis of a clinical sample) with a textual output string.
- the test-type token identifies which one of a possible plurality of interpretation tests to perform on the collected (real-time) data during the interpretation phase.
- the discriminant function table 410 is used to systematically set forth an assay's set of discriminant functions. Each row in the discriminant function table implements a single discriminant function and includes entries for (1) the assay's name, (2) a unique row identifier, (3) one or more classification parameters upon which to evaluate, (4) high and low discriminant values for each of the listed classification parameters, and (5) evaluation tokens which are assigned as a result of evaluating the discriminant function.
- the results table 415 is used to store, or accumulate, data on an assay's beadset during the real-time analysis phase of the inventive method and is discussed further in Section 6.2(d).
- the interpretation table 420 provides a means to associate text messages with each enumerated assay result and is discussed further in Section 6.2(e).
- the assay's beadset is comprised of four bead subsets, each labeled for a different analyte.
- the assay beadset is to be processed by a Becton-Dickinson Immunocytometry Systems "FACSCAN” flow cytometer. For each bead processed, the "FACSCAN” measures forward light scatter, side light scatter, red fluorescence, orange fluorescence, and green fluorescence.
- classification parameter C be forward light scatter
- classification parameter C 2 be side light scatter
- classification parameter C 3 be red fluorescence
- classification parameter C 4 be orange fluorescence
- measurement parameter F ml be green fluorescence.
- each subset is characterized by a mean ( ⁇ ) and standard deviation ( ⁇ ) for each of its four classification parameters. See Figure 5.
- ⁇ mean
- ⁇ standard deviation
- the precise number of individual beads contained in any given bead subset can be calculated by those of ordinary skill in the art. This calculation is required to obtain good statistical characterization of the subset's parameters - e.g., small, or relatively fixed, coefficient of variations for each parameter.
- the assay definition table 405 is comprised of general information relevant to the overall diagnostic function of the assay.
- each of the assay's subset's may be assigned a token used for identification: e.g., token 46 represents the bead subset labeled to detect a wildtype coding sequence for a specified gene: subset tokens 21, 50, and 5 represent subsets labeled to detect various mutant type coding sequences for a specified gene(s).
- measurement parameter E represents the bead subset labeled to detect a wildtype coding sequence for a specified gene: subset tokens 21, 50, and 5 represent subsets labeled to detect various mutant type coding sequences for a specified gene(s).
- measurement parameter E represents the bead subset labeled to detect a wildtype coding sequence for a specified gene: subset tokens 21, 50, and 5 represent subsets labeled to detect various mutant type coding sequences for a specified gene(s).
- measurement parameter E represents the bead subset labeled
- test-type token of '0' means an OV ⁇ R/UND ⁇ R interpretation test is to be performed and a test-type token of ' 1' means a SHIFT interpretation test is to be performed. See Section 6.2(f) for further discussion of these issues.
- Discriminate functions are generated by viewing the assay's baseline data graphically in three dimensions and creating planes to separate the different subset clusters. These "planes" are created by applying Fischer's Linear Discriminant to the ⁇ -dimensional classification parameter space.
- a populated discriminate function table based on the baseline data of Figure 5 is shown in Figure 7.
- the discriminant function table provides a systematic means of evaluating a series of classification values (C C 2 , C 3 , C 4 ) in order to classify a bead.
- bead classification proceeds by entering the discriminant function table at row 0, performing a test on a specified parameter (e.g., C,, C 2 , C 3 , or C 4 ) and then, depending upon the result, either classifying the bead or proceeding to another test which involves evaluating a different row in the table.
- a specified parameter e.g., C, C 2 , C 3 , or C 4
- Classification of bead A via the discriminant function table of Figure 7 begins as follows (the pseudo-code below would demonstrate to those skilled in the art of programming the logic involved in the classification process):
- a discriminant function table embodies a (classification) decision tree.
- Figure 8 shows this relationship for the discriminant function table of Figure 7 explicitly.
- a discussion of the discriminant function table as it relates to the real-time processing of an exposed assay beadset is provided in Section 6.2(d). Once a beadset is preprocessed, the data may be employed in real-time analysis of many assays using that set.
- a bitmap or look up table could be used to classify the bead sets.
- the beadset may be exposed to a test sample. That is, they may be used to analyze a clinical sample. After exposure the beadset is ready for real-time analysis.
- the real-time analysis phase is initiated by installing the exposed beads into a conventional flow cytometer for processing.
- a flow cytometer 100 For each bead processed a flow cytometer 100 generates electrical signals indicative of a plurality of measured parameters, C; ... C Cincinnati, F m] ... E TOt . These values are transmitted to computer 105 via data bus 110 and interface board 115. Values for a bead's classification parameters Cj ... C combat are used to evaluate the assay's discriminant functions, as encoded in a discriminant function table 410, the result of which is an initial classification of the bead into one of the assay's bead subsets or a reject class.
- C Pain can be checked against their (C, ... C Economics) baseline values to determine if it is "reasonable" to classify the bead as belonging to the initially identified class.
- this reasonableness test is implemented by computing the distance between the measured classification parameter values and the mean values obtained during preprocessing. If the measured values for C, ... C n for a particular bead are sufficiently distant from the identified subsets baseline values, the bead is assigned to a reject class. Use of this technique allows for the rejection of beads that were initially misclassified and improves the overall reliability of the analysis.
- pooled beadset will include a bead subset which has no bound reactants (e.g., a placebo bead subset) in a known ratio to the headset's other subsets.
- a bead subset which has no bound reactants (e.g., a placebo bead subset) in a known ratio to the headset's other subsets.
- FIG. 9 shows, in block diagram form, the general steps performed during the realtime analysis phase of a method in accordance with the invention.
- the following data are accumulated in the results table for each class (subset) of bead in the assay: (1) total count of the number of beads detected in the specified class, (2) a running sum for each measurement parameter F ml - F ⁇ , (3) for each measurement parameter the total count of the number of beads in the class whose measurement value is less than the parameter's baseline value, and (4) for each measurement parameter the total count of the number of beads in the class whose measurement value is more than the parameter's baseline value.
- the assay beadset is designed to simultaneously detect four analytes using four classification parameters ( represents forward light scatter, C 2 represents side light scatter, C 3 represents red fluorescence, and C, represents orange fluorescence) and one measurement parameter (F ml representing green fluorescence).
- a flow cytometer 100 which processes each bead (e.g., measures parameters C,, C 2 , C 3 , C 4 , and F, nl ) and transmits to computer 105 signals indicative of these measurements via data bus 110 and interface board 115.
- the bead is given a final classification of reject. Otherwise the bead's final classification is the same as its initial classification - 50.
- the COUNT value reflects the total 30 number of beads of the specified class that have been identified during the analysis. 3. Adding the bead's F m! value to the value contained in the row's SUM column.
- the SUM value reflects a running sum of the identified classes measurement values.
- the OVER COUNT value reflects the total number of beads of the specified class that have been processed whose F ml values are above that of baseline.
- the UNDER COUNT value reflects the total number of beads of the specified class that have been processed whose F ml values are below that of baseline.
- data i.e., count, and measured F m , values
- count, and measured F m , values can also be collected.
- the user may select to see a text based presentation or interpretation of the assay's numerical results.
- the assay's real-time numerical results are associated with textual explanations. These textual explanations can be displayed to the user.
- each row in the interpretation table provides the necessary information to make a single interpretation and typically includes entries for (1) the assay's name, (2) a subset token identifying the class or subset on which the interpretation is based, (3) an outcome identifier for the identified subset, (4) a test-type token, (5) high and low discriminant values for each measurement parameter utilized in the identified test, and (6) a text string describing the row's result.
- the test-type token identifies which one of a possible plurality of interpretation tests to perform on the collected (real-time) data during the interpretation phase.
- the test-type token is either '0' or '1 '.
- a value of '0' indicates an OVER/UNDER interpretation test is to be performed.
- a value of '1' indicates a SHIFT interpretation test is to be performed.
- the OVER/UNDER test is generally used for qualitative measurements where the level of reactivity of beads is an indication of the condition or concentration of a biomolecule present in the sample.
- the shift test is used where the result sought is a determination of the a minimally detectable level of a particular biomolecule.
- One of ordinary skill will recognize that many other tests could be performed. Examples include ranking, stratification, ratio of means to a standard, or to each other, etc.
- an interpretation table 420 may associate any number of, entries or
- interpretations e.g., rows within the table
- bead subset Y could have a single measurement parameter (F mI ) associated with it and this measurement parameter could indicate, depending upon its value, that one or more interpretations are appropriate.
- Figure 11 shows a sample interpretation table for this assay. Interpretation of the assay's real-time numerical results is initiated by, for example, the user selecting "interpret results" via the inventive method's graphical user interface.
- each bead subset (class) within an assay has an entry or row in the results table, Figure 10.
- the general procedure for interpreting an assay's real-time numerical results is shown in flow-chart form in Figure 12.
- each row of the results table is matched against every row in the interpretation table with the same subset token. If the result of performing the specified test is between the identified row's low and high values, then the associated textual message is displayed to the user.
- the next results table row is evaluated. This process is repeated until the every row in the interpretation table has been compared to the appropriate results table entry.
- subset 50 results table entry.
- the subset's token, 50 is used to identify three rows in the interpretation table (having outcome IDs of 1, 2, and 3) that contain information regarding evaluation of the mutant analyte.
- the test-type token indicates a SHIFT type interpretation test is to be performed. Performing this test, as defined above, yields:
- the result of the interpretation phase is a series of textual messages that describe the results of the assay.
- Conclusion of the interpretation phase marks the end of the assay.
- Assay definition, discriminant function definition, and interpretation tables are created at the time an assay beadset is created.
- Baseline classification data is collected only once for a given assay. That is, once an assay is defined and its baseline data is obtained, any number of beadsets can be manufactured to perform the analysis. To allow this "sharing" of baseline data the assay beadset may contain a center or calibration bead subset.
- a calibration beadset can be used to adjust any given flow cytometer to a standard. Calibration beadsets are typically processed separately from an assay. Further, calibration is generally performed daily. The purpose of calibration is to adjust the sensitivity of a flow cytometer's photomultipliers to accommodate day to day and machine to machine differences.
- Assays for antibody are widely used in medicine and clinical analysis for an wide variety of purposes, from detection of infections to determination of autoantibody.
- the following example illustrates use of the inventive method in an antibody assay and assumes the use of a flow cytometer capable of providing at least five measurements for each bead processed: forward light scatter as classification parameter C h side light scatter as classification parameter C 2 , red fluorescence as classification parameter C 3 . orange fluorescence as classification parameter C 4 , and green fluorescence as measurement parameter F mI .
- a number of bead subsets e.g., subsets 1 through 10 (identified as sSl- sSlO), are prepared, for example, by using a cell sorter to sort a heterogeneous population to collect a homogeneous subset or alternatively, by preparing the beads using tightly controlled specifications to ensure production of a homogeneous subset.
- Each subset is distinguishable by its characteristic pattern of classification parameters C j: C 2 , C 3 , and C 4 .
- the beads in each subset are then labeled with a different antigen such as AgA, AgB, etc.
- Antigens AgA through AgJ may be attached to the beads by any of a number of conventional procedures such as by chemical or physical absorption as described by Colvin et al., "The Covalent Binding of Enzymes and Immunoglobulins to Hydrophilic Microspheres” in Microspheres: Medical and Biological Applications, 1-13, CRC, Boca Raton, FL, 1988; Cantarero et al., "The Adsorptive Characteristics of Proteins for Polystyrene and Their Significance in Solid-Phase Immunoassays," Anal. Biochem., 105, 375-382 (1980); and Ilium et al., "Attachment of Monoclonal Antibodies to Microspheres," Methods in Enzymol., 112, 67-84 (1985).
- the pooled set is prepared with equal volumes of beads from each subset, so that the set contains about the same number of beads from each subset.
- the assay beadset may then be incubated with a fluid sample of interest, such as serum or plasma, to test for the presence of antibodies in the fluid that are reactive with antigens on the beads.
- a fluid sample of interest such as serum or plasma
- Such incubation will generally be performed under conditions of temperature, pH, ionic concentrations, and the like that facilitate specific reaction of antibodies in the fluid sample with antigen on the bead surface.
- the beads in the mixture are centrifuged, washed and incubated (again under controlled conditions) for another period of time with a "secondary" antibody such as, for example, fluorescein labeled goat anti human immunoglobulin.
- the secondary antibody will bind to and fluorescently label antibodies bound to antigen on the beads.
- the beads are processed by the flow cytometer and the four classification parameters forward light scatter , side light scatter, red fluorescence, and orange fluorescence are measured and used to identify the subset to which each bead in the assay beadset belongs.
- a simultaneous measurement of green fluorescence (measurement parameter) for each bead allows one to determine whether the bead has antibody bound to it. Because the subset to which a bead belongs is correlated with the presence of a particular antigen, e.g., sSl-AgA, one may readily determine the specificity of the antibody bound to a bead as a function of the subset to which it belongs.
- each of four samples e.g., blood serum from four patients
- the reactions were incubated at room temperature for 45 minutes, and then analyzed on the "FACSCAN" using side light scatter ( ), orange fluorescence (C 2 ), and red fluorescence (C 3 ) as classification parameters.
- Green fluorescence was used as the measurement parameter (F m ); an increase in green fluorescence by 30-fold indicates a specific interaction between an antigen and its corresponding fluorescinated antibody.
- the assay database was built, it was tested by running 5,000 beads from each bead subset individually through the system. After rejecting 23.8% of the beads as doublets, the remaining crimson beads (subset 18) were classified with 99.88% accuracy. Dark red beads
- the three bead subsets were pooled to form an assay beadset and divided into 4 sample tubes and processed by the system shown in Figure 1.
- the contents of each sample and the mean measured fluorescence (F m ) for each bead subset are listed in Figure 13e.
- the inventive method correctly identified the antibody or antibodies present in each sample.
- an Experimental Refinement In an alternative embodiment using a C 4 (e.g., orange fluorescence) labeled reactant as a classification parameter, a variety (for example five) of protein antigens are employed. Bead subsets are first generated based on differences in one or more of C,, C 2 , and C 3 . Next, a selected antigen labeled with Cy3NHS (an orange fluorophore) is bound to the beads in each subset. To minimize the measured orange fluorescence coefficient of variation for each bead subset, the beads are sorted with a high speed cell sorter so that only a narrow range of antigen (orange fluorophore) is found on each bead within a subset.
- C 4 e.g., orange fluorescence
- the measured intensity of C 4 for AgA should differ from the measured intensity of C 4 from AgB, etc.
- saturation binding with fluoresceinated monoclonal antibody is tested - each bead ought to have restricted ranges of both orange and green fluorescence. While the construction of beadsets by this method is more laborious, the increase in measurement precision may be useful and will allow the sampling of fewer beads to arrive at a suitable determination of antibody concentration.
- the assays previously mentioned measure any antibody with specificity for antigen upon an appropriately labeled bead.
- the antigen can be quite simple or rather complex and thus, the inventive methods can measure a highly restricted antibody or a broad array of antibodies.
- a hexapeptide just large enough to bind to a monoclonal antibody can be employed as antigen or a large protein with many epitopes can be used.
- the level of antibody eventually found associated with the bead (F ml ) is a function of the number of epitopes per bead, the concentration of epitopes, the amount of antibody and the affinity of the antibody and the valence of the antibody-antigen interaction.
- Displacement Assays for many substances in a clinical laboratory are based on the interference with specific ligand-ligate or antigen-antibody interactions.
- one member of the ligand-ligate pair is labeled with the F m fluorophore and one member is immobilized on the beads.
- Soluble, unlabeled material (analyte) ,which may be ligand or ligate, is added to the reaction mixture to competitively inhibit interaction of the labeled component with the immobilized component. It is usually not important which member of the pair is labeled and which is immobilized; however, in certain assays, functional advantages may dictate the orientation of the assay.
- each bead subset is modified with an antigen.
- the antigen-coated beads are then reacted with an F m labeled antibody specific for the antigen on the bead surface.
- Subsequent addition of a test fluid containing soluble analyte (inhibitor) will displace the F m labeled antibody from the beads in direct proportion to the concentration of the soluble analyte.
- a standard curve of known analyte concentrations is used to provide accurate quantification of analyte in the test sample.
- the fluid containing the beadset may be subjected to dissociating conditions such as a change in pH, ionic strength or temperature, after mixtu r e of the beadset with the sample to be tested.
- dissociating conditions such as a change in pH, ionic strength or temperature
- the F m labeled component may be added to the beadset after addition of the test sample. In either case, it is not necessary for equilibrium to be achieved to determine analyte concentration if the kinetics and linearity of the assays have been established.
- a competitive inhibition analysis is used to quantitate levels of selected analytes, here IgG, IgA, and IgM.
- a second experimental refinement demonstrates the utility of multiplexed assays in epitope mapping of a monoclonal antibody.
- that approach involved the use of antibody detection technology using a fluoresceinated monoclonal antibody in combinatorial epitope screening (e.g. of peptide libraries) to map a particular epitope to which a monoclonal antibody of interest bound, together with a displacement (competitive inhibition) aspect to demonstrate the specificity of the assay.
- ToRCH assay for screening of human serum for antibodies to a number of infectious agents known to pose special hazards to pregnant women. Allergy screening is exemplified by detection of serum IgE against a panel of grass antigens. Yet an additional experimental example reflects the ability of the multiplexed assay in pregnancy testing, e.g. in testing for hormones or other analytes commonly elevated during pregnancy. Each of these examples is set forth below. Simultaneous competitive inhibition assay of human immunoglobuling G, A and M levels in serum
- This example illustrates the determination of multiple analyte levels in a liquid sample simultaneously using competitive inhibition analysis.
- the use of a competitive inhibition assay to accurately determine analyte levels in liquid solutions is a commonly used format for many analyte assays.
- the uniqueness of this assay is the simultaneous determination of three distinct serum proteins at the same time in the same tube from one serum sample.
- Immunoglobulins G, A and M are three distinct serum proteins whose levels are determined by a number of genetic and environmental factors in human serum. As changes to these levels may indicate the presence of disease, clinicians often request assay determinations of IgG, A and M using conventional techniques. The most common technique is nephelometry that depends upon the absorption of light by precipitates formed between these immunoglobulins and antibodies made in animals to the human immunoglobulins. As these immunoglobulins are present in human serum at fairly high levels, this type of assay is sufficient. Nephelometry however suffers from a number of limitations including the need for large quantities of reagents, long reaction times for precipitation to equilibrate and an inability to perform more than one reaction per tube or sample.
- each assay consists of a DFM coated with the immunoglobulin of choice and a polyclonal, goat anti- human Ig labeled with a green fluorescent molecule (Bodipy). In the absence of inhibitor, the Bodipy -antibody causes the immunoglobulin (Ig) coated microsphere to emit green fluorescence (F m ). In the presence of inhibitor (soluble Ig), the green signal is reduced.
- DFM Differentially Fluorescent Microspheres
- Antigen conjugation to microspheres Four DFM (5.5 ⁇ M carboxylate. Bangs Laboratories, Inc.
- microspheres were washed twice with 500 ⁇ L PBS, pH 7.4 using centrifugation at 13,400 x g for 30 seconds to harvest the microspheres.
- washed beads were suspended in 250 ⁇ L of a 0.05 mg/mL solution of protein in PBS, pH 7.4.
- the microspheres were blocked by addition of 250 ⁇ L of 1.0 mg/mL BSA, 0.02% Tween, 0.2 M glycine, in PBS, pH 7.4 and incubated for an additional 30 minutes.
- Protein coated microspheres were washed twice with 500 ⁇ L 0.02% Tween 20, 1 mg/mL BSA in PBS, pH 7.4 (PBSTB). and stored in PBSTB at approximately 3,000,000 microspheres/mL. Microsphere concentrations were determined using a hemacytometer.
- Cross reactivity assay Equivalent amounts of each of the four protein loaded microspheres were mixed to produce a bead mixture. 10 ⁇ L of the bead mixture (7,500 microspheres) was mixed with 10 ⁇ L of diluted serum calibrators of known Ig level. The assay was initiated by addition of 10 ⁇ L of one of the Bodipy-labeled antibodies "spiked" with a small quantity of soluble Ig antigen to alleviate the "hook effect". The mixtures were incubated for 30 minutes, diluted to 300 ⁇ L in PBSTB and assayed by flow cytometry. As before for the single analyte assay, the Bodipy-labeled goat anti-hlgG was used at 30 ⁇ g/mL.
- the Bodipy-labeled goat anti- hlgA was used at 8 ⁇ g/mL.
- the Bodipy-labeled goat anti-hlgM was used at 2.5 ⁇ g/mL.
- the quantities of antigen "spikes" were 1.6 ⁇ g/mL for IgG, 0.6 ⁇ g/mL for IgA and 0.4 ⁇ g/mL for IgM.
- the Bodipy-labeled goat anti-hlgG was used at 30 ⁇ g/mL.
- IgA the Bodipy-labeled goat anti-hlgA was used at 8 ⁇ g/mL.
- the Bodipy-labeled goat anti-hlgM was used at 2.5 ⁇ g/mL.
- the quantities of antigen "spikes" were 1.6 ⁇ g/mL for IgG, 0.6 ⁇ g/mL for IgA and 0.4 ⁇ g/mL for IgM.
- IgG single analyte assay Results of the single analyte inhibition analysis for IgG level is shown in Table 1 and Figure 15A. This assay was designed to be most sensitive to inhibition in the anticipated range of IgG in human serum at a 1 :500 dilution. In Figure 15A, the area of the inhibition curve between the dotted lines, left and right, cover the range of sensitivity. In this case, the inhibitor was known amounts of human IgG from a serum calibrator diluted into human serum containing no IgG, IgA or IgM. Dilutions of the calibrator were then diluted 1 :500 in PBSTB and included as inhibitor in the assay.
- the Bodipy-labeled anti-hlgG was used at 30 ⁇ g/mL in PBSTB. 7,500 microspheres were used in this experiment and 250 were counted by flow cytometry. Note that as the amount of soluble IgG increased, the degree of inhibition as monitored by the MIF of F m increased proportionally until saturation of the system was achieved. On the other end of the inhibition curve note that the lower levels of soluble inhibitor caused an elevation in the MIF of F m as compared with the negative control (human serum with no Ig).
- This "hook effect” is common in immunoassay and can be adjusted up or down the inhibition curve by adjusting both the amount of antibody and antigen in the soluble portion of the assay. The "hook effect” was most prominent in the IgG assay due to the higher concentrations of both antigen and antibody per microsphere. This was necessary as IgG is found in serum at higher concentrations than IgA or IgM.
- IgA single analyte assay Results of single analyte inhibition analysis for IgA level is shown in Table 1 and Figure 15B. This assay was designed to be most sensitive to inhibition in the anticipated range of IgA in human serum at a 1:500 dilution. In Figure 15B, the area of the inhibition curve between the dotted lines, left and right, cover the range of sensitivity. In this case, the inhibitor was known amounts of human IgA from a serum calibrator diluted into human serum containing no IgG, IgA or IgM. Dilutions of the calibrator were then diluted 1 :500 in PBSTB and included as inhibitor in the assay.
- the Bodipy-labeled anti-hlgA was used at 8 ⁇ g/mL in PBSTB. 7,500 microspheres were used in this experiment and 250 were counted by flow cytometry. Note that as the amount of soluble IgA increased, the degree of inhibition as monitored by the MIF of F Dock, increased proportionally until saturation of the system was achieved. On the other end of the inhibition curve note that the lower levels of soluble inhibitor cause a slight elevation in the MIF of F, administrat as compared with the negative control (human serum with no Ig). The "hook effect" was much less pronounced for both IgA and IgM due to their lower concentrations in serum.
- IgM single analyte assay Results of single analyte inhibition analysis for IgM level is shown in Table 1 and Figure 15C. This assay was designed to be most sensitive to inhibition in the anticipated range of IgM in human serum at a 1:500 dilution. In Figure 15C, the area of the inhibition curve between the dotted lines, left and right, cover the range of sensitivity. In this case, the inhibitor was known amounts of human IgM from a serum calibrator diluted into human serum containing no IgG, IgA or IgM. Dilutions of the calibrator were then diluted 1:500 in PBSTB to be included as inhibitor in the assay..
- the Bodipy-labeled anti-hlgM was used at 2.5 ⁇ g/mL in PBSTB. 7,500 microspheres were used in this experiment and 250 were counted by flow cytometry. Note that as the amount of soluble IgM increased, the degree of inhibition as monitored by the MIF of F m increased proportionally until saturation of the system was achieved. On the other end of the inhibition curve note that the lower levels of soluble inhibitor cause a slight elevation in the MIF of F m as compared with the negative control (PBS with no added IgM). The "hook effect" is much less pronounced for both IgA and IgM due to their lower concentrations in serum.
- Cross reactivity analysis To determine the cross-reactivity of the various assay components, a multiple analyte assay was performed using only one of the three Bodipy-labeled antibodies. Equivalent numbers of the IgG, IgA, IgM and BSA beads were mixed to make a GAM mixed bead set. To 10 ⁇ L of the bead set (7,500 microspheres) was added 10 ⁇ L of dilutions of the calibrator containing IgG, IgA and IgM. The multiple analyte assay was then performed using only one of the Bodipy-labeled anti-IgG, IgA or IgM preparations rather than a mixture.
- Table 2 and Figures 16A, 16B, and 16C show the results of these assays. Results indicated that Anti- IgG-Bodipy only reacted with DFM-IgG Bodipy and not the IgA or IgM beads. No cross- reactivity with IgA or IgM was noted and the assay was validated for further multiple analyte analysis. Also added to this analysis was the antigen "spike". By adding a small amount of soluble antigen to the probe antibody solution the "hook effect' can be minimized. Note in the IgG cross-reactivity experiment that the MIF of F, constitu for negative control is higher than the lowest concentration of inhibitor. By spiking the experiment with 1 .6 ⁇ g/mL IgG the hook effect has no effect at the lower end of inhibitor range leading to a more accurate assay over the entire dynamic range.
- GAM simultaneous analysis Equivalent numbers of the IgG, IgA, IgM and BSA beads were mixed to make a GAM mixed bead set. To 10 ⁇ L of the bead set (7,500 microspheres) was added 10 ⁇ L of dilutions of the calibrator containing IgG, IgA and IgM. Also included were several additional calibrators that served as unknowns for the demonstrative purpose of this assay. The multiple analyte assay was then initiated by adding 10 ⁇ L of a mixture of the Bodipy-labeled anti-IgG, IgA and IgM plus the soluble Ig "spikes".
- This example demonstrates the screening of combinatorial chemistry products for a biologically active molecule.
- the generation of random chemical products for empirical discovery of biologically significant molecules is a method that holds great promise for progress in numerous disciplines of science including biology, pharmacology and medicine.
- One general problem with the technique is the screening of large numbers of unique molecules for a specific activity. Screening methods are required that provide high throughput levels of screening with adequate specificity and sensitivity for detection of the biological event in question.
- a monoclonal antibody (MAB 384) was chosen that was produced using the spleen cells of a mouse hyper-immunized with a defined peptide (amino acid 67-74) from the amino acid sequence of human myelin basic protein (MBP). Using the amino acid sequence of this region of MBP, nine overlapping octapeptides were synthesized that covered the predicted epitope. To the carboxyl terminal end of each peptide, glycine-lysine-biotin residues were added.
- MAB 384 (Chemicon International, Inc., Temecula, CA) was labeled with Bodipy FL-X (Molecular Probes, Inc., Eugene, OR) using methods described by the manufacturer of the Bodipy succinymidyl ester. Absorbance at 280 nm and 504 nm revealed that the resulting Bodipy-labeled antibody had a Bodipy to protein ratio of 3.31 and was stored in PBS containing 1 mg/mL BSA as stabilizer.
- microspheres were washed twice with 100 ⁇ L PBS, pH 7.4 using centrifugation at 13,400 x g for 30 seconds to harvest the microspheres. Activated, washed beads were suspended in 50 ⁇ L of a 0.25 mg/mL solution of Neutravidin in PBS, pH 7.4. After 2 hours, the microspheres were blocked by addition of 50 ⁇ L of 0.2 M glycine, 0.02% Tween 20 in PBS, pH 7.4 and incubated for an additional 30 minutes.
- Protein coated microspheres were washed twice with 100 ⁇ L 0.02% Tween 20, 1 mg/mL BSA in PBS, pH 7.4 (PBSTB) and stored in PBSTB at approximately 3,000,000 microspheres/mL as determined by hemocytometer count.
- Peptide attachment to microspheres Each of the nine DFM conjugated to Neutravidin were treated separately with one of the nine biotinylated peptides. 10 ⁇ L of biotinylated peptides at 100 - 200 ng/mL was mixed with 10 ⁇ L of microspheres and reacted for 5 minutes followed by 2 x 100 ⁇ L washes in PBSTB. The peptide loaded microspheres were suspended in 20 ⁇ L of PBSTB.
- peptides to be screened The amino acid sequence upstream and downstream from the epitope of monoclonal antibody MAB 384 (amino acid 67-74, YGSLPQ, SEQ ID NO. 2) was determined using the published amino acid sequence (Roth, H.J., et al., J. Neurosci. Res.. 17, 321-328, 1990). The table below shows the amino acid sequence of the nine overlapping peptides produced for the screening assay. Note that to the carboxy-terminal end of all peptides was added a glycine (G)-lysine (K)-biotin.
- G glycine
- K glysine
- Bodipy-MAB 384 at 15.5 ⁇ g/mL. After 60 minutes, the mixture was assayed using flow cytometry and results (MIF of F m ) are also shown in Figure 21. Both assays minus added peptide are shown as a negative control. Results indicated that peptide #5 contained the epitope for MAB 384. Peptides #4 and #6 although containing 3 of the epitope's amino acids showed little reactivity. The multiple and single analyte assays provided identical results. Numerical data is shown in Table 6. Competitive inhibition using soluble epitope peptide: To further demonstrate the specificity of the assay, soluble peptide containing the epitope (#5) was used to inhibit the reaction shown in Figure 21.
- This epitope mapping example demonstrates the useful application of the instant invention to the area of combinatorial screening.
- the peptide carrying the epitope for the mouse monoclonal antibody screened in this example was clearly identified in a set of nine peptides. The identification was further shown to be specific by competitive inhibition with soluble epitope peptide. In addition, the stability of the avidin-biotin interaction for use with flow cytometry was demonstrated in an excess of free biotin.
- This example demonstrates the utility of this invention in the screening of human serum for antibodies to infectious disease agents. Screening of serum for antibodies to certain infectious disease agents is often the only method available to determine if a patient has been, or is infected with the agent in question. For example, a common method of diagnosing HIV infection is by detection of HIV specific antibodies in the serum. This phenomenon known as seroconversion is commonly employed for diagnosis of several important pathogenic infections.
- One of the most commonly employed assay panels of this type is the ToRCH panel ToRCH assays detect both serum IgG and serum IgM responses to Toxoplasma gondii, Rubella virus, Cytomegalovirus, and Herpes Simplex Virus Types 1 and 2.
- Antibody labeling Goat anti-human IgG and goat anti-human IgM (Cappel Division, Organon Teknika, Durham, NC) were labeled with Bodipy FL-CASE (Molecular Probes, Inc., Eugene, OR) using methods described by the manufacturer of the Bodipy succinymidyl ester. Bodipy- labeled antibodies were stored in PBS containing 1 mg/mL BSA as stabilizer.
- Antigen conjugation to microspheres Five DFM (5.5 ⁇ M carboxylate, Bangs Laboratories, Inc., Carmel, IN, dyed by Emerald Diagnostics, Inc., Eugene, OR) were conjugated separately to the five ToRCH antigens (Viral Antigens, Inc.) with a two-step EDC coupling method (Pierce Chemicals, Rockford, IL) using sulfo-NHS to stabilize the amino-reactive intermediate. All antigens were dialyzed into PBS to remove any reactive amino groups such as sodium azide or glycine. The T.
- gondii preparation (Chemicon, Inc., Temecula, CA) was sonicated for 2 minutes in PBS, 10 mM EDTA to lyse the tachyzoites.
- 20 ⁇ L (8.4 million microspheres) of each bead type was activated for 20 minutes in a total volume of 100 ⁇ L containing 500 ⁇ g of EDC and Sulfo-NHS in 50 mM sodium phosphate buffer, pH 7.0.
- Microspheres were washed twice with 200 ⁇ L PBS, pH 7.4 using centrifugation at 13,400 x g for 30 seconds to harvest the microspheres.
- Activated and washed beads were suspended in 100 ⁇ L of antigen at 0.05 to 0.15 mg/mL in PBS, pH 7.4. After 2 hours, the microspheres were blocked by addition of 100 ⁇ L of 0.2 M glycine, 0.02% Tween 20 in PBS, pH 7.4 and incubated for an additional 30 minutes. Antigen coated microspheres were washed twice with 200 ⁇ L 0.02% Tween 20, 1 mg/mL BSA in PBS, pH 7.4 (PBSTB). and stored in PBSTB at approximately 3,000,000 microspheres/mL as determined by hemacytometer count.
- Rubella assay Rubella antigen loaded microspheres were used to examine several parameters of the assay in a single analyte format prior to the performance of multiple analyte assays. 10 ⁇ L (30,000 microspheres) of Rubella antigen coated beads were reacted with 10 ⁇ L of a 1 : 10 dilution of four different Rubella calibrator sera (Consolidated Technologies, Inc., Oak Brook, IL) and the mixture incubated for 1 hour. These sera were defined using a standard assay for the anti-Rubella IgG activity by the manufacturer of the calibrators. The units were defined as International Units/ mL or IU/mL.
- Beads were washed in PBSTB by centrifugation at 13,400 x g for 30 seconds and suspended in 40 ⁇ L of a 10 ⁇ g/mL solution of Bodipy-labeled anti-human IgG. This mixture was incubated for 1 hour, diluted to 300 ⁇ L in PBSTB and assayed using flow cytometry. Negative controls included the microspheres with no serum treated with the Bodipy-labeled antibodies. In addition one calibrator serum containing 70 IU/mL of anti- Rubella IgG activity was titrated in a single analyte assay.
- ToRCH IgG activities as defined by INX and DiaMedix diagnostic instruments. These values were provided by the manufacturer for the lot of calibrator purchased. Beads were washed in
- PBSTB by centrifugation at 13,400 x g for 30 seconds and suspended in 20 ⁇ L of a 40 ⁇ g/mL solution of Bodipy-labeled anti-human IgG or IgM. This mixture was incubated for 1 hour, diluted to 300 ⁇ L in PBSTB and assayed using flow cytometry. Negative controls included the microspheres with no serum treatment and the microspheres treated with the ToRCH negative control serum. Both negative controls were developed with the Bodipy-labeled antibodies.
- Rubella assay Rubella coated DFM were reacted with 4 human serum calibrators containing known levels of IgG antibodies specific for Rubella virions defined by International units (IU/mL). The beads were washed and developed with goat anti-human IgG-Bodipy. Results are shown in Table 9 and Figure 24. Increasing units of anti-Rubella activity were reflected in the Mean Intensity of Fluorescence (MIF) of F m (green channel). Luminex Units (LU) were defined as the MIF of F m for each data point minus the MIF of F Outdoor, for the negative control (no serum) multiplied by 0.1, and are included in Table 9.
- MIF Mean Intensity of Fluorescence
- LU Luminex Units
- Rubella calibrator titration The human serum calibrator containing 70 IU/mL of anti-Rubella IgG was serially diluted in PBSTB and assayed with the Rubella coated microspheres and Bodipy-labeled anti-human IgG. Results shown in Table 10 and Figure 25 show that, as expected, the IgG antibodies specific for Rubella were titrated with dilution.
- the known levels of anti-ToRCH IgG reactivities for the ToRCH Calibrator were compared to the Luminex units of each IgG activity as determined by the multiple analyte analysis. Luminex units were defined by subtracting the negative control serum average MIF of F m from the average MIF of F m for each antigen and multiplying by 0.1. The levels of the ToRCH calibrator were defined by the manufacturer as a factor of activity for each antigen above the limit of detection for that antigen on a specific diagnostic machine. These results are listed in Table 13.
- a demonstrative ToRCH assay has been developed to simultaneously assay for serum IgG or IgM specific for the five ToRCH pathogens in a single tube. Results of the assay indicate that it is specific for each pathogen and is as sensitive as currently available instrument based assays.
- the multiple analyte format provides a uniquely powerful technology for rapid and less expensive serum testing for seroconversion to ToRCH pathogens as well as other infectious agents diagnosed in this manner.
- This example demonstrates the screening of serum for IgE antibodies specific for allergens. Screening of serum for IgE antibodies specific to allergens is a viable option for allergy testing as compared with skin sensitivity testing.
- the instant invention provides for a format that can assay for either IgG or IgE responses to numerous allergens at the same time in the same tube with the same sample and is therefore a uniquely powerful method of screening.
- An allergy assay has been developed including 16 grass allergens in a multiple analyte, simultaneous format.
- a panel of 16 grass allergens were attached to 16 Differentially Fluorescent Microspheres (DFM) with one grass allergen being coated onto one unique member of the bead set.
- the allergen bead set was treated with diluted dog serum for 1 hour and treated with a solution of either Goat anti-Dog IgE or goat anti-dog IgG-FITC for an additional hour.
- beads were washed clear of this antibody and the bead set treated with an affinity purified rabbit anti-goat IgG-FITC antibody as probe.
- Results demonstrate a uniquely powerful method of serum screening for allergies that provides a true multiple analyte format, as well as sensitivity and specificity.
- Allergen conjugation to microspheres Sixteen DFM (5.5 ⁇ M carboxylate) were conjugated separately to 16 soluble grass allergens (provided by Dr. Bill Mandy, BioMedical Services, Austin, TX) with a two-step EDC coupling method (Pierce Chemicals, Rockford, IL) using sulfo-NHS to stabilize the amino-reactive intermediate. All grass allergens were diluted 1 :100 into PBS, pH 7.4. 20 ⁇ L (8.4 million microspheres) of each bead type was activated for 20 minutes in a total volume of 100 ⁇ L containing 500 ⁇ g of EDC and Sulfo-NHS in 50 mM sodium phosphate buffer, pH 7.0.
- Microspheres were washed twice with 100 ⁇ L PBS, pH 7.4 using centrifugation at 13,400 x g for 30 seconds to harvest the microspheres. Activated, washed beads were suspended in 50 ⁇ L of diluted allergen. After 2 hours, the microspheres were blocked by addition of 50 ⁇ L of 0.2 M glycine, 0.02% Tween 20 in PBS, pH 7.4 and incubated for an additional 30 minutes. Protein coated microspheres were washed twice with 100 ⁇ L 0.02% Tween 20, 1 mg/mL BSA in PBS, pH 7.4 (PBSTB). and stored in PBSTB at approximately 3,000,000 microspheres/mL as determined by hemacytometer count.
- Simultaneous K-9 grass allergen IgG assay Equivalent amounts of each of the 16 grass allergen loaded microspheres was mixed to produce a bead mixture. 20 ⁇ L (8.4 million microspheres) of the mixture was reacted with 20 ⁇ L of a 1 : 10 dilution of dog serum in PBSTB and the mixture incubated for 1 hour. Beads were washed in 200 ⁇ L PBSTB by centrifugation at 13,400 x g for 30 seconds and suspended in 25 ⁇ L of a 50 ⁇ g/mL solution of goat anti-dog IgG-FITC. After one hour the bead mixture was diluted to 300 ⁇ L in PBSTB and assayed using flow cytometry.
- MIF mean intensity of fluorescence
- This example illustrates the determination of multiple analyte levels in a liquid sample simultaneously by immunometric or capture-sandwich assay.
- capture-sandwich assays to accurately determine analyte levels in liquid solutions is a commonly used format for many analyte assays.
- the technique is especially useful for those analytes present in low quantities as the first step serves to capture and thus concentrate the analyte.
- the uniqueness of this assay is the multiple analyte format allowing the simultaneous determination of two distinct serum proteins at the same time in the same tube from the same serum sample.
- hCG Human chorionic gonadotropin
- AFP Alpha fetoprotein
- AFP is the fetal cell equivalent to human serum albumin.
- AFP is elevated in pregnancy and in certain types of malignancies.
- Many clinical fertility or pregnancy test panels include immunometric assays for these two serum proteins. Immunometric or capture-sandwich assays for hCG and AFP were developed separately and then combined in a multiple analyte format. The hCG assay was developed by examining several antibody pairs for their ability to capture and quantitate hCG levels in solution. First, a monoclonal antibody was coupled through carbodiimide linkage to a carboxylate substituted Differentially Fluorescent
- Antibody labeling The two affinity purified polyclonal anti-hCG (AB633) and anti-AFP (M20077) antibodies (Chemicon, Inc., Temecula, CA and Medix Division. Genzyme, San Carlos, CA) were labeled with Bodipy FL-CASE (Molecular Probes, Inc., Eugene, OR) using methods described by the manufacturer of the Bodipy succinymidyl ester. The resulting Bodipy-labeled antibodies were stored in PBS containing 1 mg/mL BSA as stabilizer.
- Antibody conjugation to microspheres Monoclonal anti-hCG (MAB602) and anti-AFP (SI 0473) capture antibodies were conjugated to microspheres with a two-step EDC coupling method (Pierce Chemicals, Rockford, IL) using sulfo-NHS to stabilize the amino-reactive intermediate. 20 ⁇ L ( 8.4 million microspheres) of each DFM was activated for 20 minutes in a total volume of 100 ⁇ L containing 500 ⁇ g of EDC and Sulfo-NHS in 50 mM sodium phosphate buffer, pH 7.0. Microspheres were washed twice with 200 ⁇ L PBS, pH 7.4 using centrifugation at 13,400 x g for 30 seconds to harvest the microspheres.
- Capture assay antibody pairs were screened by coupling potential capture antibodies to microspheres and assaying them using all potential combinations of capture antibody-bead/ Bodipy-labeled probe antibody. Assays were performed using 10 ⁇ L of capture antibody microspheres (approximately 30,000) plus 20 ⁇ L of antigen solution at 10 ⁇ g/mL in PBSTB for a 1 hour incubation. Beads were washed in PBSTB by centrifugation at 13,400 x g for 30 seconds and suspended in 20 ⁇ L of a 25 ⁇ g/mL solution of Bodipy-labeled probe antibody. This mixture was incubated for 1 hour, diluted to 300 ⁇ L in PBSTB and assayed using flow cytometry.
- Antigen titration assay Once an antibody pair was chosen for use, the pair was analyzed for sensitivity and limit of detection by titration of antigen. Assays were performed using 10 ⁇ L of capture antibody microspheres plus 20 ⁇ L of antigen dilutions in PBSTB for a 1 hour incubation. Beads were washed in 200 ⁇ L PBSTB by centrifugation at 13,400 x g for 30 seconds and suspended in 20 ⁇ L of a 25 ⁇ g/mL solution of Bodipy-labeled probe antibody. This mixture was incubated for 1 hour, diluted to 300 ⁇ L in PBSTB and assayed using flow cytometry.
- Washed vs. no-wash assay format An AFP/hCG capture antibody bead mixture was made by mixing equal amounts of the two bead types. In duplicate, 10 ⁇ L of this bead mixture (10,000 microspheres) was mixed with 20 ⁇ L dilutions of AFP/ hCG and incubated for 1 hour. One set n ⁇ chronological, M . PCT/US99/00918
- AFP and hCG antibody pairs were shown not to cross-react and were adjusted to provide clinically relevant ranges of sensitivity in a homogenous assay, the assays were performed simultaneously using commercially available serum calibrators as the source of AFP and hCG antigens. Equivalent amounts of each of the two capture antibody loaded microspheres was mixed to produce an AFP/hCG capture mixture. In triplicate, 10 ⁇ L of this bead mixture (5,000 of each microsphere) was mixed with 20 ⁇ L of three serum calibrators (high, medium and low) containing known levels of AFP and hCG and incubated for 1 hour.
- Mixtures were treated directly with 20 ⁇ L of a blend of Bodipy-labeled anti-hCG and anti-AFP both at 25 ⁇ g/mL. Mixtures were incubated for 1 hour, diluted to 300 ⁇ L in PBSTB and assayed by flow cytometry.
- Antibody pair analysis for hCG capture assay For hCG antibody pair analysis, five capture antibody/microspheres were prepared and the identical five antibodies were Bodipy-labeled to serve as probes. Three of the antibodies were specific for the alpha sub-unit of hCG and two for the beta sub-unit. The three anti-alpha sub-unit antibody'microspheres were assayed for utility with the two Bodipy-labeled anti-beta hCG antibodies. Conversely, the two anti-beta sub-unit antibody/microspheres were assayed for utility with the three Bodipy-labeled anti-alpha hCG antibodies. Results of this screen are shown in Table 14 and Figure 35.
- the 12 combinations of antibodies are shown with (odd numbers) and without (even numbers) hCG at 20 ⁇ g/mL. It is apparent that the first two antibody pairs, #1 and #3 demonstrated the highest mean intensity of fluorescence (MIF) of the F m (green channel). Further examination of these two pairs led to the decision to chose the #3 pair of MAB 602 for capture antibody and AB633-Bodipy as probe antibody for the hCG capture/sandwich assay.
- MIF mean intensity of fluorescence
- Antigen titration The MAB 602/AB633 anti-hCG capture system was assayed by hCG titration to determine if the level of sensitivity required for clinical assay was achievable. A limit of detection of at least 1 ng hCG/mL was the target as this was the level of hCG in the low serum calibrator to be used later in this project. The results of this antigen titration is shown in Table 15 and Figure 36. The limit of detection was between 20 and 200 pg/mL. This revealed that the MAB602/AB633 anti-hCG antibody pair was sufficiently sensitive for hCG analysis. Included in this analysis was MIF of F m measurements from counting of 100 or 1000 microspheres. Results were similar. A similar analysis of antibody pairs and antigen titration for AFP identified an AFP pair that could be further developed.
- Cross-reactivity assay The MAB 602/AB633 anti-hCG capture system and S-10473/M20077 anti-AFP capture system were examined for cross reactivity by assaying each capture bead with each antigen and Bodipy-labeled antibody. Results are shown in Table 16 and Figures 37A and 37B. No significant cross-reactivity between the hCG and AFP capture systems was detected.
- No-wash vs. washed assay format The hCG and AFP assays were performed simultaneously and examined for the limit of quantitation or dynamic range in both a washed format and no wash or homogenous format. Result of these antigen titrations are shown in Table 17 and Figures 38A and 38B. Results indicated that the homogenous format provided sufficient dynamic range for the purposes of clinical relevance.
- hCG/AFP assay Multiple analyte hCG/AFP assay: The two assays were performed simultaneously using serum calibrators of known hCG and AFP levels to generate a standard curve. For each standard curve one serum of unknown hCG and AFP level was included to demonstrate how the assay would determine the level of hCG and AFP in the serum.
- the Randox Tri-level calibrators consisted of three serum samples with high, medium and low levels of hCG and AFP documented in mU or U/mL for hCG and AFP respectively. These calibrators are used in at least 12 different diagnostic instruments including those of Abbott (Abbott Park, IL), bioMerieux (St.
- Literature with the Randox Tri-Level control listed the units of each known analyte as defined by each diagnostic machine. We calculated the average of the hCG mU/mL and AFP U/mL for the three calibrators. In the case of the hCG, the low and medium calibrators contained 22.8 and 26.4 mU/mL which were extremely close considering the distance to the high calibrator (436 mU/mL).
- Level 3D a fourth level serum calibrator termed Level 3D.
- Calibrator 3D was only used in construction of the hCG standard curve so each of the assays was effectively defined by three point calibration.
- Table 18 shows the results of this multiple analyte assay.
- the assay was performed in triplicate and the average MIF of F m computed for graphing. Coefficients of variation (CV) for the triplicates were consistently less than 10% are shown. Also included in the table are the number of microspheres correctly identified by the flow cytometry out of the 400 counted per tube. Of the 400 beads counted the expected ratio of MAB 602 containing 60/40 beads to S- 10473 containing 40/60 beads was 1:1. Therefore of the 200 beads expected, this was the number of beads correctly identified and used to compute the MIF of F m for that data point.
- CV coefficients of variation
- Figures 39A and 39B graphically represent the data of Table 18.
- a plot of the MIF vs. the log of antigen concentration produced a line that was best fit using a third level polynomial equation.
- the fit for the hCG curve provided an R of 1.0 and for AFP an R of 0.9999 was achieved.
- the concentration of the unknowns was computed. Results of these analyses are seen in Table 18.
- the unknown serum contained 218.55 ⁇ 6.56 mU/mL of hCG and 39.59 ⁇ 1.19 U/mL of AFP.
- a demonstrative immunometric assay for hCG and AFP in serum has been developed.
- Assays were first developed as single analyte or single bead assays, and optimized with regards to sensitivity, limit of quantitation and cross-reactivity. The assays were then combined to quantitatively determine multiple analyte levels in a liquid solution in the same tube from the same sample at the same time. Results, using commercially available calibrator sera, has proven that this invention is effective for this type of quantitative assay.
- This example provides a demonstration of the measurement of ligand-ligate reactions using a multiplexed beadset standard curve.
- ligand-ligate reactions quantitation, known amounts of the ligand or ligate are introduced to the reaction leading to the production of a standard curve. Values for unknown samples are compared to the standard curve and quantified.
- the true multiple assay capability of this invention allows for an additional type of standard to be utilized.
- a multiplexed beadset standard curve for measuring analyte concentration is created by using several Differentially Fluorescent Microspheres (DFM) coated with either 1) different amounts of ligand (antigen), or 2) different amounts of ligate (antibody), or 3) different ligates possessing different avidities for the ligand (different monoclonal antibodies).
- DFM Differentially Fluorescent Microspheres
- microspheres were washed twice with 200 ⁇ L PBS, pH 7.4 using centrifugation at 13,400 x g for 30 seconds to harvest the microspheres.
- washed beads were suspended in 50 ⁇ L of hlgG at 50, 10. 5, and 1 ⁇ g/mL in PBS, pH 7.4.
- the microspheres were blocked by addition of 50 ⁇ L of 0.2 M glycine, 0.02% Tween 20 in PBS, pH 7.4 and incubated for an additional 30 minutes.
- Protein coated microspheres were washed twice with 200 ⁇ L 0.02% Tween 20, 1 mg/mL BSA in PBS, pH 7.4 (PBSTB). and stored in PBSTB at approximately 3,000,000 microspheres/mL as determined by hemacytometer count.
- Antibody labeling Goat anti-human IgG (Cappel Division, Organon Teknika, Durham, NC) was labeled with Bodipy FL-CASE (Molecular Probes, Inc., Eugene, OR) using methods described by the manufacturer of the Bodipy succinymidyl ester. The resulting Bodipy-labeled antibody was stored in PBS containing 1 mg/mL BSA as stabilizer.
- Multiplexed beadset standard curve Equivalent amounts of each of the 4 differentially loaded IgG microspheres was mixed to produce a bead mixture. 10 ⁇ L of the goat anti-hlgG-Bodipy at 25 ⁇ g/mL in PBSTB was mixed with 10 ⁇ L of a dilution of hlgG in PBSTB. Immediately 10 ⁇ L (30,000 microspheres) of the bead mixture was added and the mixture incubated at room temperature for 30 minutes. Beads were diluted to 300 ⁇ L in PBSTB and assayed using flow cytometry. A negative control included the microspheres with the goat anti-hlgG-Bodipy with no inhibitor (hlgG).
- Each bead subset was assigned the value of a consecutive integer (i.e. the bead subset coupled with the lowest concentration of IgG was given a value of 1 , the next highest concentration was given a value of 2, etcetera) and those numbers plotted against the MIF of each bead subset at each concentration of inhibitor tested.
- the slopes (designated here as inter-bead subset slopes) were computed using linear regression analysis. The inter-subset slopes were then plotted against the concentration of inhibitor using a logarithmic scale for the concentration of inhibitor. Results were plotted as the slope of the MIF of F m across the bead set against the log of hlgG concentration. Curve fitting was performed using a power function trendline and the R correlation was reported.
- Multiplexed beadset standard curve for a competitive inhibition assay Four differentially loaded IgG microspheres were utilized in a multiple beadset competitive inhibition assay for hlgG at five different concentrations of soluble inhibitor (hlgG). Results of the assay are shown in Table 19. The inhibition pattern on each bead is plotted in Figure 40. The inter-bead subset slopes are plotted against the log concentration of inhibitor in Figure 41. A Power Trendline in Excel was used to produce the R of 0.9933.
- Advantages of the multiplexed beadset standard curve include the inclusion of the standard curve microspheres in each point of a multiplexed beadset assay, and the extension of an assay's dynamic range. This may be achieved by increasing the concentration range of ligand or ligate on the microspheres or b> increasing the range of avidities for ligand on a series of microspheres.
- a major advance in this area is here. That advance employs a flow cytometric bead- based hybridization assay which permits the extremely rapid and accurate detection of genetic sequences of interest.
- a bead to which a nucleic acid segment of interest has been coupled is provided.
- a PCR product of interest (or any other DNA or cDNA segment) is detected by virtue of its ability to competitively inhibit hybridization between the nucleic acid segment on the bead and a complementary fluorescent nucleic acid probe.
- the method is so sensitive and precise as to allow the detection of single point mutations in the PCR product or nucleic acid of interest.
- the further discovery of methods of multiplexing such an analysis compounds the method's power and versatility to allow simultaneously analysis of a number of nucleic acid products or a number of sequences within a single product in a single sample.
- the multiplexed DNA analysis method described here can be applied to detect any PCR product or other DNA of interest for specific polymorphisms or mutations or for levels of expression, e.g. mRNA.
- a beadset containing subsets of beads coupled to nucleic acid sequences of interest is prepared by coupling a unique synthetic or purified DNA sequence to the beads within each subset.
- Fluorescent probes complementary to the DNA coupled to each bead subset are prepared. Methods known in the art, e.g., as described in U.S. Patent No. 5,403,71 1 , issued April 4, 1995 and incorporated herein by reference, or other methods may be used to fluorescently label the DNA. Since each probe will bind optimally only to its complementary DNA- containing subset, under the conditions of the assay, the fluorescent probes may be added to the subsets before or after the subsets are pooled, and before or after addition of the DNA test sample(s) of interest.
- Tissue, fluid or other material to be analyzed is obtained, and DNA is purified and/or amplified with PCR as necessary to generate the DNA products to be tested.
- the DNA samples of interest are then mixed with the pooled beadset under suitable conditions to allow competitive hybridization between the fluorescent probes and the DNA of interest.
- each bead subset is then analyzed by flow cytometry to determine the reactivity of each bead subset with the DNA sample(s). If the test sample contains a DNA sequence complementary to the DNA of a given bead subset then that subset will exhibit a decreased F m value relative to the F m value of beads to which a control DNA has been added.
- a computer executed method in accordance with the current invention can determine the subset from which each bead is derived, and therefore, the identity of the DNA sequence on the bead and any change in F m .
- the methods of the present invention find wide utility in the detection of foreign DNA's in, for example, diagnostic assays.
- the DNA segment to be analyzed can be any DNA sequence
- the selected segment will be a DNA segment of a pathogenic organism such as, but not limited to, bacterial, viral, fungal, mycoplasmal, rickettsial, chlamydial, or protozoal pathogens.
- the procedure has particular value in detecting infection by pathogens that are latent in the host, found in small amounts, do not induce inflammatory or immune responses, or are difficult or cumbersome to cultivate in the laboratory.
- the multiplexed DNA detection method of the present invention is likely to find particular utility as a diagnostic assay for analysis of a sample from a patient having clinical symptoms known to be caused by a variety of organisms using a beadset designed to detect DNAs from the variety of organisms known to cause such symptoms to determine which of such organisms is responsible for the symptoms.
- DNA would be extracted from tissue, fluid or other sources and analyzed as described above.
- the invention may also be used to measure a variety of genetic polymorphisms in a target DNA of interest. For example, there are several genes in the MHC and many are polymorphic. There are at least two applications in which determination of the alleles at each position of the MHC is of critical importance. The first is the determination of haplotype for transplantation, and the second is determination of haplotype as indicator of susceptibility to disease. See Gross et al., "The Major Histocompatibility Complex-Specific Prolongation of Murine Skin and Cardiac Allograft Survival After In Vivo Depletion of V ⁇ + T Cells," J. Exp. Med., 177, 35-44 (1993).
- the MHC complex contains two kinds of polymorphic molecules, Class I genes, HLA A, B and D which have 41, 61 and 18 known alleles and Class 10 genes, HLA-DRI,3,4,5 HLA-DQAI and Bl HLA-DP, DPA1, DPB1, also with many alleles.
- Class I genes HLA A, B and D which have 41, 61 and 18 known alleles and Class 10 genes, HLA-DRI,3,4,5 HLA-DQAI and Bl HLA-DP, DPA1, DPB1, also with many alleles.
- HLA-DRI hepatocyte-D
- Bl HLA-DP hepatocyte-D
- DPA1, DPB1 co-dominant Class 10 genes
- a multiplexed assay in accordance with the invention may be employed to perform tissue typing quickly and accurately to identify suitable matches for transplantation.
- DNA is obtained from blood or other extractable source, and amplified with primers specific for the MHC genes under analysis, for example, HLA-DQA.
- primers specific for the MHC genes under analysis for example, HLA-DQA.
- HLA-DQA For a full genotyping of the MHC, several samples of DNA would be amplified with different sets of primers to accommodate the large number of loci and the high degree of polymorphism.
- the PCR products are then screened for specific alleles using beadsets and fluorescent probes as described above.
- a given genetic locus or multiple loci, can be simultaneously screened for the presence of wild type or mutant sequences.
- multiple known mutations can be distinguished from each other and from the wild type sequence and uncharacterized mutations.
- the homozygosity or heterozygosity of known sequences can be determined.
- a general approach for detecting a DNA mutation in accordance with this aspect of the invention is as follows.
- a suitable probe for detecting a mutation of interest is selected.
- selected oligonucleotides, representing wild-type and mutant sequences, from a region of a gene known to contain a mutation are prepared.
- Such oligonucleotides are coupled to microspheres by techniques known in the art, (e.g., carbodiimide coupling, or other means) to produce individual aliquots of beads having known oligonucleotides coupled thereto.
- the oligonucleotides must be a sufficient length to allow specific hybridization in the assay, e.g., generally between about 10 and 50 nucleotides, more preferably between about 20 and 30 nucleotides in length. In a preferred embodiment, a saturating amount of the oligonucleotide is bound to the bead. Fluorescent oligonucleotides, complementary to all or part of the sequences attached to each bead, are also prepared.
- PCR primers are selected to amplify that region of the test DNA corresponding to the selected probe, which are then used to amplify the particular region of DNA in the sample that contains the sequence corresponding to the oligonucleotide coupled to the beads. Either double stranded or single stranded PCR techniques may be used. If double stranded product is produced, the amplified PCR product is made single stranded by heating to a sufficient temperature to and for a sufficient time to denature the DNA (e.g., for about 1 ,to about 5 minutes at about 90-95°C in 2.3X SSC hybridization buffer).
- the mixture is cooled, and the beads are added and incubated with the PCR product under conditions suitable to allow hybridization to occur between the oligonucleotide on the beads and the PCR product (e.g., at room temperature for about 10 minutes).
- the fluorescent DNA probe may then be added and the entire mixture incubated under hybridization conditions suitable to allow competitive hybridization to occur (e.g., 5 minutes at 65°C, then cooling to room temperature over a period of several hours in 2.3X SSC buffer).
- concentrations of the PCR product and fluorescent probe to be used may vary and may be adjusted to optimize the reaction.
- the concentrations of PCR product and fluorescent probe to be used are adjusted so as to optimize the detectable loss of fluorescence resulting from competitive inhibition without sacrificing the ability of the assay to discriminate between perfect complementarity and one or more nucleotide mismatches.
- the concentration of PCR product complementary to the oligonucleotide bound to the beads may be on the order of 1 to 10 times the molar concentration of fluorescent probe used.
- the fluorescent probe should preferably be added in an amount sufficient to achieve slightly less than saturation of the complementary oligonucleotide on the beads in order to obtain maximum sensitivity for competitive inhibition.
- beadsets are separately prepared, pooled, and the bead-based hybridization analysis performed.
- beadset subsets are prepared such that subset 1 is coupled to a DNA segment identical to the wild type sequence, subset 2 is coupled to a DNA segment identical to a known mutation 1 (which may represent a single or multiple point mutations, deletions or insertions), subset 3 is coupled to a DNA segment identical to a second known mutation 2, and so on.
- the subsets are then mixed to create a pooled beadset.
- test sample is less inhibitory than the perfectly complementary sequence for any of the known sequences represented by the subsets then a new uncharacterized mutation is indicated.
- the test sample could then be sequenced to characterize the new mutation, and this sequence information used to construct a new subset for the beadset to detect the newly discovered mutation.
- the present invention has wide-spread advantages for detection of any of a number of nucleic acid sequences of interest in the genomic DNA of an individual or organism and has the advantages of being both rapid and extremely accurate in effecting the detection of such mutations.
- the invention will find wide applicability in diagnosis of a number of genetically associated disorders as well as in other applications where identification of genetic mutations may be important.
- Exemplary diseases include without limitation, diseases such as cystic fibrosis, generalized myotonia and myotonia congenita, hyperkalemic periodic paralysis, hereditary ovalocytosis, hereditary spherocytosis and glucose malabsorption; which are associated with mutations in the genes encoding ion transporters; multiple endocrine neoplasia, which is associated with mutations in the MEN2a, b, and MEN1 genes; familial medullary thyroid carcinoma, and Hirschsprung's disease, which are associated with mutations in the ret proto-oncogene; familial hypercholesterolemia, which is associated with mutations in the LDL receptor gene; neurofibromatosis and tuberous sclerosis, which are associated with mutations in the NF1 gene, and NF type 2 gene; breast and ovarian cancer, which are associated with mutations in the BRC A 1 , BRCA2, BRCA3 genes; familial adenomatouspolyposis, which is associated with mutation
- Double Stranded the two complementary strands of a double-stranded DNA segment are referred to as strand “A” and strand “B". Either strand may be designated “A” or “B”.
- the wild-type "B” strand oligo (ras codon 12) having the oligonucleotide sequence 5'- GCCTACGCCACCAGCTCCAACTAC-3 ' (SEQ ID NO. 3) was coupled to 3.0 micrometers ( ⁇ m) latex microspheres (manufactured by Interfacial Dynamics, Portland, OR) by carbodiimide coupling.
- Double stranded competitor was prepared by combining equal amounts of both the "A” and “B” strands of either the wild-type or mutant version of the oligo, mutant "B” strand having the sequence 5'-GCCTACGCCACAAGCTCCAACTAC-3' (SEQ ID NO. 4) (ras codon 12) in 5X SSC buffer. Annealing was accomplished by heating the mixture to 65°C for five minutes, then cooling slowly to room temperature.
- Competitive hybridization was accomplished by combining approximately 40 picomoles of the bead-attached oligo (wild-type "B” strand) with the indicated amounts of double stranded competitor in 2.3X SSC buffer at approximately 25°C.
- PCR products were derived from the DQAl gene, in the region of the gene which determines the major alleles of DQAl .
- the DQAl gene represents the DNA coding sequence for the alpha chain of the DQ molecule.
- DQ is classified as a class II histocompatibility locus and is expressed in allelic form in all humans. Most individuals are heterozygous for DQA , i.e., they express two different DQA alleles. The determination of DQA alleles is used in identity testing for paternity and forensic purposes.
- Flow cytometry was used to determine the presence or absence of all fourteen DNA sequences in a PCR product simultaneously in a single reaction tube, thereby allowing determination of the DQA alleles expressed in a given sample.
- the system is based on competitive hybridization between the PCR product and complementary oligonucleotide pairs representing each of the fourteen unique DNA sequences.
- One strand of each oligonucleotide pair is coupled to a unique subset of microspheres and the complementary strand is labeled with a green emitting fluorophore. After coupling, the fourteen unique microsphere subsets were pooled to produce the mixed bead set.
- the mixture After addition of the fourteen fluorescent oligonucleotides and the PCR product to the beadset, the mixture is hybridized and then analyzed by flow cytometry. The ability of the PCR product to inhibit the hybridization of the complementary fluorescent oligonucleotides to their respective microsphere subsets is used to determine the DNA sequences, and thus, the allele(s) present in the PCR product.
- Microspheres Carboxylate-modified latex (CML) microspheres of 5.5 micron mean diameter were obtained from Bangs Laboratories, Inc. (Carmel, IN). The microspheres were differentially dyed with varying concentrations of two fluorescent dyes with orange and red emission spectra to produce fourteen unique microsphere subsets.
- CML Carboxylate-modified latex
- Oligonucleotides Fourteen oligonucleotide pairs (complementary strands designated "A” and "B") corresponding to allelic sequences within the DQAl gene (Table 22) were synthesized by Oligos, Etc. (Wilsonville, OR), using standard automated techniques. Each eighteen-base oligonucleotide was substituted at the 5' end with an amino-terminal linker during synthesis.
- Oligonucleotide coupling to microspheres The "B" strand of each oligonucleotide pair was coupled to a unique subset of CML microspheres using carbodiimide chemistry. Briefly, 0.1 mL of a 1 mM solution of oligonucleotide in 0.1 M MES (2-[N-morpholino]ethanesulfonic acid), pH 4.5 was added to 1.0 mL of microspheres (1% solids) in 0.1 M MES, pH 4.5.
- EDC l-ethyl-3-[3-dimethylaminopropyl]- carbodiimide hydrochloride
- Oligonucleotide labeling The "A" strand of each oligonucleotide pair was fluorescently labeled with Bodipy FL-X (6-((4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl) amino)hexanoic acid, succinimidyl ester) (Molecular Probes, Inc. , Eugene, OR).
- Tissue sample (template) DNA was purified using the QIAmp Blood Kit (Qiagen, Chatsworth, CA) for DNA purification. Briefly, 1 x 10 7 tissue culture cells or 200 ⁇ L whole blood is lysed with* Qiagen protease and Buffer AL. The lysate is incubated at 70°C for 10 minutes followed by addition of 210 ⁇ L ethanol. The mixture is applied to a QIAmp spin column and centrifuged at 8,000 x g for 1 minute. The filtrate is discarded, 500 ⁇ L Buffer AW is added to the column and the centrifugation is repeated; this step is repeated. The filtrates are discarded and the DNA is eluted into a new tube by addition of 200 ⁇ L Buffer AE, incubation at room temperature for 1 minute, followed by centrifugation as above.
- QIAmp Blood Kit Qiagen, Chatsworth, CA
- PCR primers designated DQA AMP-A (5'-ATGGTGTAAA CTTGTACCAGT-3', SEQ ID NO. 5) and DQA AMP-B (5'-TTGGTAGCAG CGGTAGAGTTG-3', SEQ ID NO. 6) (World Health Organization, 1994) were synthesized by Oligos, Etc. (Wilsonville, OR) using standard automated techniques. PCR was performed with reagents (PCR buffer, dNTPs, MgCl 2 , and TAQ DNA polymerase) from Life Technologies, Inc.(Gaithersburg, MD).
- the reaction mixture (50 ⁇ L) contained 1 ⁇ M of each primer, 200 nM dNTPs, 3 mM MgCl 2 , 4 - 10 ⁇ g/mL DNA template, and 2.5 units TAQ DNA polymerase in PCR buffer.
- the PCR reaction was performed on an Idaho Technologies thermal cycler (Idaho Falls, ID) using and initial step at 94°C for 45 sec, and 32 cycles of 94°C for 30 sec, 48°C for 60 sec, and 72°C for 60 sec followed by a final hold at 72°C for 7 minutes.
- the hybridization reaction was performed in a total volume of 40 ⁇ L, containing approximately 8,000 of each bead subset for a total of approximately 110,000 microspheres, 50 nM of each fluorescent oligonucleotide, and 10 - 200 nM PCR product, as competitor, in hybridization buffer (3 M trimethyl ammonium chloride, 0.15% sodium dodecyl sulfate, 3 mM EDTA, and 75 mM TrisHCl, pH 8.0).
- hybridization buffer 3 M trimethyl ammonium chloride, 0.15% sodium dodecyl sulfate, 3 mM EDTA, and 75 mM TrisHCl, pH 8.0.
- the beadset mixture in hybridization buffer, was equilibrated at 55°C.
- the mixture of fluorescent oligonucleotides and PCR product was denatured in a boiling water bath for 10 minutes followed by quick-chilling on ice for 2 minutes.
- the microspheres were added, mixed well, and the entire reaction was allowed to hybridize for 30 minutes at 55°C.
- the mixture was diluted to 250 ⁇ L using hybridization buffer and analyzed by flow cytometry.
- FIG. 45 illustrates the classification, using orange and red fluorescence, of the fourteen microsphere subsets used in the DQAl analysis. Each distinct microsphere subset bears one of the fourteen unique oligonucleotide capture probes on its surface. The level of green fluorescence associated with each subset, after hybridization with the fluorescent oligonucleotide probes, is also determined simultaneously, and measures the reactivity of the fluorescent oligonucleotides (and therefore, the reactivity of the PCR product) with each unique oligonucleotide sequence.
- FIG. 46 illustrates the hybridization of increasing concentrations of fluorescent oligonucleotide "5503A” to microspheres coupled to oligonucleotide "5503B” in the presence or absence of a 200 nM concentration of double-stranded 0301 PCR product which contains the 5503 sequence.
- the level of "5503A” which hybridizes to the microspheres, detected as FLI increases in a linear manner and reaches saturation at approximately 10 nM.
- Figure 47 illustrates the inhibition of fluorescent oligonucleotide hybridization by varying concentrations of complementary and point mutant competitors in the presence of a fixed concentration of fluorescent oligonucleotide.
- the solid lines show the inhibition of hybridization to bead "340 IB” induced by competitors 3401 (u) or 3402 (n).
- the dashed lines show inhibition of hybridization to bead "3402B” induced by competitors 3401 (s) or 3402 (I). Even at the lowest competitor concentration (10 nM), there is approximately a two-fold difference between the reactivity of the identical sequence versus the point mutant.
- Allele-specific reactivity patterns In order to establish the reactivity patterns of the DQAl alleles in a model system, simulated alleles were prepared by mixing the oligonucleotides representing the DNA sequences that would be present within a single PCR product for a given allele.
- Figure 49 illustrates the typing of four simulated alleles of DQAl . By comparison to the allele reactivity chart shown in Table 24, it can be seen that each of the simulated alleles types correctly.
- Typing of homozygous genomic DNA To verify the ability of flow cytometry to correctly type PCR products prepared from genomic DNA, samples of DNA of known, homozygous DQAl type were obtained from the UCLA Tissue Typing Laboratory, Los Angeles, CA. After PCR amplification, these samples were typed using flow cytometry; the results are shown in Figure 50. By comparison to the allele reactivity chart (Table 24), it can be seen that the system correctly types these samples.
- Typing of heterozygous genomic DNA To determine the ability of multiplexed flow analysis to accurately type heterozygous DQAl haplotypes, twenty-five samples of known heterozygous DQAl type were obtained from the UCLA Tissue Typing Laboratory, Los Angeles, CA.
- the invention may also be used in several formats for measurement of enzymes, enzyme inhibitors and other analytes.
- bead subsets can be generated that are modified with selected fluorescent substrates which can be enzymatically cleaved from the bead, resulting in a loss of fluorescence (F m ).
- Enzymes that can be detected and measured using the invention include but are not restricted to, protease, glycosidase, nucleotidase, and oxidoreductase. Any enzyme that results in selected bond cleavage can be measured.
- a cartoon of the action of enzyme on a bead-bound enzyme is shown in Figure 51a.
- An enzyme that acts upon a bead- bound substrate so that the bead-bound substrate becomes fluorescent or loses fluorescence comprises an assay for the level of enzyme affecting such a change.
- Alteration of the substrate could be an oxidation or reduction, alteration of a chemical bond such a hydrolysis or other alteration of the bead-bound substrate so that the fluorescence of the substrate is altered in intensity or spectrum.
- Enzymes that act upon pro-enzymes can be measured using a bead-bound substrate providing the reaction mixture contains the pro-enzyme and beads bearing a substrate that can be acted upon by the active form of the enzyme. (Providing the specificity of each activated enzyme is distinct, a multiplexed assay is achievable in which several pro-enzymes can be measured at the same time.)
- the sample is introduced into a mixture of pro-enzymes under reaction conditions. After a fixed time interval during which the convertase acts upon the pro- enzyme, the beadsets specific for each enzyme generated from each pro-enzyme are added and the newly generated activities measured in a subsequent time period which is terminated when the beadsets are analyzed by flow cytometry.
- Such a process for a single pro-enzyme to enzyme conversion is illustrated by the cartoon in Figure 5 Id.
- the action of the enzyme can be measured in an indirect but facile manner using a bead bound substrate as depicted in Figure 51e.
- the action of the enzyme on the bead-bound substrate results in the formation or revelation of a ligate for a fluorescent ligand present in the reaction mixture.
- the bead bearing the modified substrate then becomes fluorescent by virtue of binding of the fluorescent ligand to the newly formed ligate.
- the enzyme(s) would be added to the beadset under reactive conditions. After a defined time period during which the enzyme acts upon the bead bound substrate, the enzyme action would be stopped and the fluorescent ligands added and after a period for association of ligand with the beadsets, the mixture analyzed by flow cytometry.
- the fluorescent ligands could be of a single reactivity or multiple ligands employed, the critical specificity is that of the enzyme for the substrate.
- the bead-bound substrate may be used to detect the activation of enzyme when the enzyme requires a cofactor for activity. Under this circumstance, the level of the cofactor becomes the limiting component of the reaction mixture and determination of the level of cofactor can be measured.
- the reaction mixture contains the bead-bound substrate as well as the apo-enzyme. After introduction of the analyte (enzyme cofactor), the reaction mixture is held under reactive conditions for a fixed period of time followed by analysis of the beads by flow cytometry, the level of cofactor limits the level of enzyme activity. Providing the enzymes present require different cofactors and have action on different substrate-bearing beadsets, several cofactors could be measured in a single assay mixture.
- bead-borne substrates can be used as reagent as are soluble substrates for enzymes.
- a mixture of bead subsets can be used to measure several enzyme activities simultaneously in the same reaction mixture.
- Fluids that can be analyzed using these techniques include plasma, serum, tears, mucus, saliva, urine, pleural fluid, spinal fluid and gastric fluid, sweat, semen, vaginal secretions, fluid from ulcers and other surface eruptions, blisters, and abscesses, and extracts of tissues including biopsies of normal, malignant, and suspect tissues.
- An assay according to this aspect of the invention proceeds as follows:
- Beads containing reactive surface groups are obtained that can be discriminated on the basis of, for example, forward angle light scatter, , right angle light scatter, C 2 , and one of several wavelengths of fluorescence C 3 ...C Crow which are designated as orange and red fluorescence, for example, and comprise a number of subsets.
- Subsets thus obtained are derivatized with a peptide (substrate) having a terminal fluorescent green group, for example fluorescein (F m ).
- a fluid to be tested is diluted with an appropriate buffer and added to the beadset mixture to allow enzymes present in the sample to react with (cleave) their corresponding substrate on the surfaces of the beads.
- reaction is stopped and the entire mixture processed by a flow cytometer and results are determined.
- the presence of an enzyme in the clinical sample is indicated by loss of fluorescence resulting from the cleavage of the fluorescent F m substrate from the bead surface. Because the beads are analyzed in a very small volume (e.g., about 6 picoliters) as they are passed through the flow cytometer's laser beam, interference from free fluorescent molecules (cleaved substrate) will not significantly interfere with the assay. This obviates the requirement of washing of the beads prior to assay and simplifies the procedure significantly.
- Time measurement is an important feature of the analysis.
- the essence of the measurement of an enzyme activity is a change in substrate with time.
- the activity can be determined by setting a period of time during which the clinical sample is in contact with the beads using standard conditions of pH, ionic composition and temperature.
- Two alternative processes are available for determination of the bead-bound substrate with time, that is the time expired while the enzyme(s) is (are) acting on each beadset(s).
- the time at which each measurement was obtained is recorded along with the bead's other measurements.
- the baseline measurement is determined.
- the enzyme clinical sample
- the sample analysis begins.
- the time data collected is used to determine the length of time that the bead has been exposed to the clinical sample.
- the F m data collected over the period of the assay is used to determine the rate of change of substrate on the beads (kinetics) and thus the rate readily derived for each bead subset in the mixture exposed to the clinical sample.
- Time can be determined and at the same time a quality control internally generated by including a "timer" bead subset that bears a substrate which is acted on by an enzyme that does not naturally occur in the clinical sample to be tested.
- the corresponding "timer” enzyme is added to the dilution buffer so that a known concentration of the "timer” enzyme is present in the buffer.
- the degree of action of the "timer" enzyme upon the beads in the "timer” subset can be measured as a function of the loss of fluorescence of the beads in the subset to ensure that proper reaction conditions are achieved.
- the level of fluorescence of the timer beads can thus be used as an internal standard and an estimation of time.
- an assay of this type may also be used to detect enzyme inhibitors or regulators.
- samples being tested for inhibitors are added to the beadset followed by the corresponding enzymes. If inhibitors are present, the measured fluorescent (F m ) values will not be decreased to the same extent as a control containing no inhibitors.
- F m fluorescent
- Figure 52 in a similar manner, inhibitors of enzyme activators or binders of cofactors can be measured.
- the interleukin-2 receptor gamma chain maps to Xql 3.1 and is mutated in X- linked severe combined immunodeficiency, SCIDX1 J. M. Puck, S. M. Deschenes, J. C. Pbrter, A. S. Dutra, C. J. Brown, H. F. Willard & P. S. Henthorrr, Cell 73: 147-57 (1993) [93214986] Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. M. Noguchi, H. Yi, H. M. Rosenblatt, A. H. Filipovich, S.
- Lesch-Nyhan syndrome S. Fujimori, B. L. Davidson, W. N. Kelley & T. D. Palella; Proc. Natl. Acad. Sci. U.S.A. 86: 1919-23 (1989) [89184538] Identification of mutati ns leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA.
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "Oligonucleotide"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "Oligonucleotide"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "Oligonucleotide"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "Oligonucleotide"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "Oligonucleotide"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "Oligonucleotide"
- clientHeight ⁇ 6912
- ClientLeft 840
- ClientTop 1452
- BorderStyle 0 'None
- BorderStyle 0 'None
- Width 375
- BorderStyle 0 'None
- Width r 375
- BorderStyle 0 'None
- Width 375
- BorderStyle 0 'None
- Width 375
- BorderStyle 0 'None
- Width 375
- Width 375
- BorderStyle 0 'None
- DatabaseName "C: ⁇ ACCESS ⁇ orbit . MDB"
- DatabaseName "C: ⁇ ACCESS ⁇ orbit.MDB"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23220/99A AU2322099A (en) | 1998-01-16 | 1999-01-15 | Multiplexed analysis of clinical specimens apparatus and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US838798A | 1998-01-16 | 1998-01-16 | |
US09/008,387 | 1998-01-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999036564A1 WO1999036564A1 (en) | 1999-07-22 |
WO1999036564A9 true WO1999036564A9 (en) | 1999-10-28 |
Family
ID=21731353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000918 WO1999036564A1 (en) | 1998-01-16 | 1999-01-15 | Multiplexed analysis of clinical specimens apparatus and methods |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2322099A (en) |
WO (1) | WO1999036564A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691594B2 (en) | 1996-04-25 | 2014-04-08 | Bioarray Solutions, Ltd. | Method of making a microbead array with attached biomolecules |
US8691754B2 (en) | 2003-09-22 | 2014-04-08 | Bioarray Solutions, Ltd. | Microparticles with enhanced covalent binding capacity and their uses |
US9147037B2 (en) | 2004-08-02 | 2015-09-29 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
US9251583B2 (en) | 2002-11-15 | 2016-02-02 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
US9360476B2 (en) | 2006-12-19 | 2016-06-07 | Fio Corporation | Microfluidic system and method to test for target molecules in a biological sample |
US9436088B2 (en) | 2001-06-21 | 2016-09-06 | Bioarray Solutions, Ltd. | Un-supported polymeric film with embedded microbeads |
US9459200B2 (en) | 2008-08-29 | 2016-10-04 | Fio Corporation | Single-use handheld diagnostic test device, and an associated system and method for testing biological and environmental test samples |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696304B1 (en) | 1999-02-24 | 2004-02-24 | Luminex Corporation | Particulate solid phase immobilized protein quantitation |
US7253435B2 (en) | 1999-04-15 | 2007-08-07 | Millipore Corporation | Particles with light-polarizing codes |
US6908737B2 (en) | 1999-04-15 | 2005-06-21 | Vitra Bioscience, Inc. | Systems and methods of conducting multiplexed experiments |
US6383740B2 (en) | 1999-07-30 | 2002-05-07 | Bioergonomics, Inc. | Methods for simultaneously detecting both members of a binding pair |
WO2001018735A2 (en) * | 1999-09-10 | 2001-03-15 | Becton Dickinson And Company | Apparatus and methods for drug analysis and development |
WO2001073443A2 (en) | 2000-03-28 | 2001-10-04 | The Government Of The United State Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the simultaneous detection of multiple analytes |
US6365355B1 (en) | 2000-03-28 | 2002-04-02 | The Regents Of The University Of California | Chimeric proteins for detection and quantitation of DNA mutations, DNA sequence variations, DNA damage and DNA mismatches |
EP1282818A2 (en) * | 2000-03-31 | 2003-02-12 | Glaxo Group Limited | Method and reagents for investigating functional molecular interactions |
US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
DE10037506A1 (en) * | 2000-08-01 | 2002-02-14 | Giesing Michael | Method for the detection of nucleic acids by means of hybridization, use of this method and corresponding analysis kit as well as nucleic acid oligomers and their use |
US7078172B1 (en) * | 2000-08-08 | 2006-07-18 | Toyo Kohan Co., Ltd. | Substrate activation kit and method for detecting DNA and the like using the same |
US7465540B2 (en) | 2000-09-21 | 2008-12-16 | Luminex Corporation | Multiple reporter read-out for bioassays |
CA2741049C (en) | 2001-10-15 | 2019-02-05 | Bioarray Solutions, Ltd. | Multiplexed analysis of polymorphic loci by probe elongation-mediated detection |
US20030109067A1 (en) | 2001-12-06 | 2003-06-12 | Immunetech, Inc. | Homogeneous immunoassays for multiple allergens |
US20030166303A1 (en) * | 2001-12-21 | 2003-09-04 | David Peritt | Novel screening method for molecular antagonist using flow-cytometry |
US7157228B2 (en) * | 2002-09-09 | 2007-01-02 | Bioarray Solutions Ltd. | Genetic analysis and authentication |
US7927796B2 (en) | 2003-09-18 | 2011-04-19 | Bioarray Solutions, Ltd. | Number coding for identification of subtypes of coded types of solid phase carriers |
JP2007521017A (en) | 2003-10-28 | 2007-08-02 | バイオアレイ ソリューションズ リミテッド | Optimization of gene expression analysis using immobilized capture probes |
US7892731B2 (en) * | 2004-10-01 | 2011-02-22 | Radix Biosolutions, Ltd. | System and method for inhibiting the decryption of a nucleic acid probe sequence used for the detection of a specific nucleic acid |
CA2571904A1 (en) * | 2006-02-15 | 2007-08-15 | Fio Corporation | System and method of detecting pathogens |
CN101484806A (en) | 2006-05-17 | 2009-07-15 | 协乐民公司 | Method for automated tissue analysis |
EP2209549A4 (en) | 2007-10-12 | 2014-03-05 | Fio Corp | Flow focusing method and system for forming concentrated volumes of microbeads, and microbeads formed further thereto |
CA2729023C (en) | 2008-06-25 | 2013-02-26 | Fio Corporation | Bio-threat alert system |
CN102348986B (en) | 2009-01-13 | 2015-05-06 | Fio公司 | A handheld diagnostic test device and method for use with an electronic device and a test cartridge in a rapid diagnostic test |
GB201002627D0 (en) | 2010-02-16 | 2010-03-31 | Loxbridge Res Llp | Aptamer based analyte detection method |
EP3553527A1 (en) | 2011-03-17 | 2019-10-16 | Cernostics, Inc. | Systems and compositions for diagnosing barrett's esophagus and methods of using the same |
MX2018015748A (en) * | 2016-06-17 | 2019-08-05 | Siemens Healthcare Diagnostics Inc | Devices, methods, and kits for multiplexing a fluid sample via fluid sample reuse. |
US20210088517A1 (en) * | 2020-09-29 | 2021-03-25 | RayBiotech Life | MULTIPLEX HIGH-THROUGHPUT FLOW CYTOMETRY DETECTION OF SARS-COV-2-SPECIFIC IgG, IgA AND IgM |
CN114184781B (en) * | 2021-12-31 | 2024-07-05 | 山西大学 | Novel pathogen antibody detection method and application thereof in detection of novel coronavirus antibody |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4673288A (en) * | 1981-05-15 | 1987-06-16 | Ratcom, Inc. | Flow cytometry |
US4665020A (en) * | 1984-05-30 | 1987-05-12 | United States Department Of Energy | Flow cytometer measurement of binding assays |
US4661913A (en) * | 1984-09-11 | 1987-04-28 | Becton, Dickinson And Company | Apparatus and method for the detection and classification of articles using flow cytometry techniques |
US4714682A (en) * | 1985-12-11 | 1987-12-22 | Flow Cytometry Standards Corporation | Fluorescent calibration microbeads simulating stained cells |
US5403711A (en) * | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
US4905169A (en) * | 1988-06-02 | 1990-02-27 | The United States Of America As Represented By The United States Department Of Energy | Method and apparatus for simultaneously measuring a plurality of spectral wavelengths present in electromagnetic radiation |
US5408307A (en) * | 1988-07-11 | 1995-04-18 | Omron Tateisi Electronics Co. | Cell analyzer |
US5224058A (en) * | 1990-05-01 | 1993-06-29 | Becton, Dickinson And Company | Method for data transformation |
US5853984A (en) * | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
US5127730A (en) * | 1990-08-10 | 1992-07-07 | Regents Of The University Of Minnesota | Multi-color laser scanning confocal imaging system |
US5286452A (en) * | 1991-05-20 | 1994-02-15 | Sienna Biotech, Inc. | Simultaneous multiple assays |
DK0642577T3 (en) * | 1992-05-22 | 2004-07-19 | Univ Montana State | Antibodies with specificity for multiple adhesion molecules |
US5367474A (en) * | 1993-02-08 | 1994-11-22 | Coulter Corporation | Flow cytometer |
-
1999
- 1999-01-15 WO PCT/US1999/000918 patent/WO1999036564A1/en active Application Filing
- 1999-01-15 AU AU23220/99A patent/AU2322099A/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691594B2 (en) | 1996-04-25 | 2014-04-08 | Bioarray Solutions, Ltd. | Method of making a microbead array with attached biomolecules |
US9400259B2 (en) | 1996-04-25 | 2016-07-26 | Bioarray Solutions, Ltd. | Method of making a microbead array with attached biomolecules |
US9436088B2 (en) | 2001-06-21 | 2016-09-06 | Bioarray Solutions, Ltd. | Un-supported polymeric film with embedded microbeads |
US9251583B2 (en) | 2002-11-15 | 2016-02-02 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
US8691754B2 (en) | 2003-09-22 | 2014-04-08 | Bioarray Solutions, Ltd. | Microparticles with enhanced covalent binding capacity and their uses |
US9147037B2 (en) | 2004-08-02 | 2015-09-29 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
US9360476B2 (en) | 2006-12-19 | 2016-06-07 | Fio Corporation | Microfluidic system and method to test for target molecules in a biological sample |
US9459200B2 (en) | 2008-08-29 | 2016-10-04 | Fio Corporation | Single-use handheld diagnostic test device, and an associated system and method for testing biological and environmental test samples |
Also Published As
Publication number | Publication date |
---|---|
AU2322099A (en) | 1999-08-02 |
WO1999036564A1 (en) | 1999-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0852004B1 (en) | Multiplexed analysis of clinical specimens | |
US6449562B1 (en) | Multiplexed analysis of clinical specimens apparatus and method | |
WO1999036564A9 (en) | Multiplexed analysis of clinical specimens apparatus and methods | |
WO1997014028A9 (en) | Multiplexed analysis of clinical specimens apparatus and method | |
US5981180A (en) | Multiplexed analysis of clinical specimens apparatus and methods | |
US6057107A (en) | Methods and compositions for flow cytometric determination of DNA sequences | |
EP0594763B1 (en) | Methods and compositions for simultaneous analysis of multiple analytes | |
Fulton et al. | Advanced multiplexed analysis with the FlowMetrixTM system | |
Tanke et al. | New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling | |
Gaipa et al. | Detection of minimal residual disease in pediatric acute lymphoblastic leukemia | |
US8394599B2 (en) | Methods and compositions for risk stratification | |
US20020107640A1 (en) | Methods for determining the true signal of an analyte | |
US20020048767A1 (en) | Method for the diagnosis of genetic diseases by molecular combing and diagnostic kit | |
Nolan et al. | Flow cytometry: a versatile tool for all phases of drug discovery | |
CN108004304B (en) | Method for detecting clonality of lymphocyte related gene rearrangement | |
AU5340599A (en) | Gel microdrops in genetic analysis | |
US20090136918A1 (en) | Quantification of microsphere suspension hybridization and uses thereof | |
US8148171B2 (en) | Multiplexed analysis of clinical specimens apparatus and methods | |
Kelesidis et al. | Assessment of telomere length, phenotype, and DNA content | |
Suni et al. | Performance of plate-based cytokine flow cytometry with automated data analysis | |
Miller et al. | The application of protein microarrays to serum diagnostics: prostate cancer as a test case | |
Morgan et al. | Modern molecular diagnostics and the management of haematological malignancies | |
US20050164261A1 (en) | Multiplexed analysis of clinical specimens apparatus and methods | |
US8615367B2 (en) | Number coding for identification of subtypes of coded types of solid phase carriers | |
US6605436B1 (en) | Method and kit for detecting intrachromosome imbalance in interphase nuclei and their applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/65-65/65, DRAWINGS, REPLACED BY NEW PAGES 1/65-65/65; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |